Document

DEF 14A 1 txg-2021def14a.htm DEF 14A Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

______________________


Filed by the Registrant			x			Filed by a Party other than the Registrant			o


Check the appropriate box:

o			Preliminary Proxy Statement

o			Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

x			Definitive Proxy Statement

o			Definitive Additional Materials

o			Soliciting Material Pursuant to §240.14a-12

10x Genomics, Inc.

(Name of Registrant as Specified In Its Charter)


Payment of Filing Fee (Check the appropriate box):

x	No fee required.

o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	1)	Title of each class of securities to which transaction applies:

	2)	Aggregate number of securities to which transaction applies:

	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	4)	Proposed maximum aggregate value of transaction:

	5)	Total fee paid:


o	Fee paid previously with preliminary materials.

o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount Previously Paid:

	2)	Form, Schedule or Registration Statement No.:

	3)	Filing Party:

	4)	Date Filed:

April 23, 2021

To Stockholders of 10x Genomics, Inc.:

Our 2021 Annual Meeting of Stockholders (“2021 Annual Meeting”) will be held on Friday, June 11, 2021 at 1:30 p.m. PDT. The 2021 Annual Meeting will be conducted exclusively online via a live webcast. You will be able to attend the meeting, submit your questions during the meeting and vote your shares electronically at the meeting by visiting www.virtualshareholdermeeting.com/TXG2021. Because the meeting is completely virtual and being conducted via the Internet, stockholders will not be able to attend the meeting physically in person. The attached notice and proxy statement describe the formal business to be transacted at the meeting.

Whether or not you attend the virtual 2021 Annual Meeting, it is important that your shares be represented and voted at the meeting. Therefore, I urge you to promptly vote and submit your proxy via regular mail, online or by telephone. The 2021 Annual Meeting is being held so that stockholders may consider:

Proposal 1: the election of Class II directors;

Proposal 2: the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and

Proposal 3: an advisory vote on the frequency of future advisory votes to approve the compensation paid to our named executive officers.

The Board recommends that you vote FOR the election of each of the nominees named in Proposal 1 of the accompanying proxy statement, FOR the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021 in Proposal 2 and for a frequency of 1 YEAR for future advisory votes to approve the compensation paid to the Company’s named executive officers in Proposal 3. Information about the matters to be acted upon at the 2021 Annual Meeting is contained in the accompanying proxy statement.

On behalf of the board of directors and the officers and employees of 10x Genomics, Inc., I would like to take this opportunity to thank our stockholders for their continued support.


			Sincerely,

			Serge Saxonov
			Chief Executive Officer and Director

Table of Contents

TABLE OF CONTENTS



			Page
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS			1
ABOUT THE MEETING			2
BOARD OF DIRECTORS AND CORPORATE GOVERNANCE			6
DIRECTOR COMPENSATION			12
PROPOSAL 1: Election of Directors			14
PROPOSAL 2: Ratification of Independent Registered Public Accounting Firm			17
PROPOSAL 3: Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation			19
AUDIT COMMITTEE REPORT			20
COMPENSATION COMMITTEE REPORT			20
EXECUTIVE OFFICERS			22
EXECUTIVE COMPENSATION			23
STOCK OWNERSHIP			39
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS			43
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS			44
OTHER MATTERS			44
PROPOSALS OF STOCKHOLDERS FOR OUR 2022 ANNUAL MEETING			45

10x Genomics, Inc.

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

Notice is hereby given that our 2021 Annual Meeting of Stockholders (“2021 Annual Meeting”) will be held virtually via live webcast on the Internet on Friday, June 11, 2021 at 1:30 p.m. PDT for the following purposes:

1.Election of Class II directors;

2.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;

3.An advisory vote on the frequency of future advisory votes to approve the compensation paid to our named executive officers; and

4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

These proposals are more fully described in the proxy statement ("Proxy Statement") following this Notice of Internet Availability of Proxy Materials ("Notice").

Our board of directors recommends that you vote: (i) FOR the election of the respective nominees for Class II directors named in the Proxy Statement to serve as directors of the Company; (ii) FOR the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and (iii) for a frequency of 1 YEAR for future advisory votes to approve the compensation paid to the Company’s named executive officers. You will be able to attend the meeting, submit your questions during the meeting and vote your shares electronically at the meeting by visiting www.virtualshareholdermeeting.com/TXG2021.

Our board of directors has fixed the close of business on April 15, 2021 as the record date for the determination of the stockholders entitled to notice of, and to vote at, the 2021 Annual Meeting. Accordingly, only stockholders of record at the close of business on that date will be entitled to vote at the 2021 Annual Meeting.

YOUR VOTE IS IMPORTANT. Whether or not you plan to attend the 2021 Annual Meeting, we urge you to submit your vote via regular mail, online or via telephone as soon as possible to ensure your shares are represented. For additional instructions for each of these voting options, please refer to the proxy card. We encourage you to vote by internet or telephone. It is convenient, conserves paper and saves 10x Genomics, Inc. postage and other costs. Returning the proxy does not deprive you of your right to attend the 2021 Annual Meeting and to vote your shares at the 2021 Annual Meeting. The Proxy Statement explains proxy voting and the matters to be voted on in more detail.

Important Notice Regarding the Availability of Proxy Materials for the 2021 Annual Meeting to Be Held on June 11, 2021. Our proxy materials, including the Proxy Statement and Annual Report on Form 10-K, are being made available on or about April 23, 2021 on our website at https://investors.10xgenomics.com in the SEC Filings section of our Investors web page, as well at the following website: www.proxyvote.com. We are providing access to our proxy materials over the Internet under the rules adopted by the U.S. Securities and Exchange Commission.


			By order of the board of directors,

			Serge Saxonov
			Chief Executive Officer and Director
			April 23, 2021

Your vote is important. To vote your shares, please follow the instructions in the Notice of Internet Availability of Proxy Materials, which is being mailed to you on or about April 23, 2021.

10X GENOMICS, INC.

PROXY STATEMENT

ANNUAL MEETING OF STOCKHOLDERS

June 11, 2021

IMPORTANT INFORMATION REGARDING DELIVERY OF PROXY MATERIALS

The Securities and Exchange Commission (the “SEC”) has adopted rules regarding how companies must provide proxy materials to their stockholders. These rules are often referred to as “notice and access,” under which a company may select either of the following options for making proxy materials available to its stockholders:

•the full set delivery option; or

•the notice only option.

A company may use a single method for all of its stockholders or use full set delivery for some while adopting the notice only option for others. In connection with our 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”), we have elected to use the notice only option.

Full Set Delivery Option

Under the full set delivery option, which we have elected NOT to use for the 2021 Annual Meeting, a company delivers all proxy materials to its stockholders by mail as it would have done prior to the change in the rules. In addition to delivery of proxy materials to stockholders, the company must post all proxy materials on a publicly-accessible website and provide information to stockholders about how to access the website. Although we have elected to use the notice only option in connection with the 2021 Annual Meeting, we may choose to use the full set delivery option in the future.

Notice Only Option

Under the notice only option, a company must post all proxy materials on a publicly-accessible website. Instead of delivering proxy materials to its stockholders, the company instead delivers a “Notice of Internet Availability of Proxy Materials.” The notice includes, among other things:

•information regarding the date and time of the 2021 Annual Meeting of stockholders as well as the items to be considered at the meeting;

•information regarding the website where the proxy materials are posted; and

•various means by which a stockholder can request paper or e-mail copies of the proxy materials.

By reducing the amount of materials that a company needs to print and mail, the notice only option provides an opportunity for cost savings as well as conservation of paper products. As stated above, in connection with our 2021 Annual Meeting, we have elected to use the notice only option. Accordingly, you will not receive all proxy materials by mail. These proxy materials include the Notice relating to the 2021 Annual Meeting, Proxy Statement, proxy card and our Annual Report on Form 10-K, which are available at www.proxyvote.com. If a stockholder requests paper copies of the proxy materials, these materials must be sent to the stockholder within three business days and by first class mail.

ABOUT THE MEETING

Our 2021 Annual Meeting will be held on Friday, June 11, 2021, at 1:30 p.m. PDT. This year’s annual meeting will be a virtual meeting via live webcast on the Internet. You will be able to attend the 2021 Annual Meeting, vote and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/TXG2021. In order to vote or submit a question during the 2021 Annual Meeting, you will need to follow the instructions posted at www.proxyvote.com and will need the 16-digit control number included on your Notice or proxy card. If you do not have a 16-digit control number, you will only be able to listen to the meeting and will not be able to vote or submit your questions during the meeting.

Why am I receiving these materials?

Our board of directors is providing these proxy materials to you in connection with the solicitation by our board of directors of proxies for use at our 2021 Annual Meeting, which will take place on June 11, 2021. Stockholders are invited to attend the 2021 Annual Meeting and are requested to vote on the proposals described in this Proxy Statement.

All stockholders will have the ability to access the proxy materials via the Internet, including this Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”), as filed with the SEC on February 26, 2021. The Notice includes information on how to access the proxy materials, how to submit your vote over the Internet, by phone or how to request a paper copy of the proxy materials. This Proxy Statement and the Annual Report are available at www.proxyvote.com.

What is the purpose of the 2021 Annual Meeting?

At our 2021 Annual Meeting, stockholders will act upon the matters outlined in the notice of meeting on the cover page of this Proxy Statement, consisting of (1) the election of Class II directors; (2) the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; (3) an advisory vote on the frequency of future advisory votes to approve the compensation paid to our named executive officers; and (4) any other matters that properly come before the meeting.

Who is entitled to vote at the 2021 Annual Meeting?

Only holders of our common stock as of the close of business on April 15, 2021, the record date, are entitled to receive notice of and to vote at the 2021 Annual Meeting. In deciding all matters at the 2021 Annual Meeting, each stockholder will be entitled to one vote for each share of our Class A common stock and ten votes for each share of our Class B common stock owned as of the record date. We do not have cumulative voting rights for the election of directors. As of the record date, there were 87,174,072 shares of our Class A common stock and 22,531,465 shares of our Class B common stock outstanding and entitled to vote. We do not have any outstanding shares of preferred stock. A list of stockholders entitled to vote at the meeting will be available for examination by any stockholder electronically during the 2021 Annual Meeting at virtualshareholdermeeting.com/TXG2021 when you enter the 16-digit control number that is shown on your Notice or on your proxy card if you elected to receive proxy materials by mail.

What constitutes a quorum?

The presence at the meeting or representation by proxy of the holders of common stock representing a majority of the voting power of the issued and outstanding shares of stock on the record date will constitute a quorum, permitting the meeting to conduct its business. Virtual attendance at our 2021 Annual Meeting constitutes presence in person for purposes of a quorum at the meeting. Each of (a) the shares held by each stockholder who properly submits a proxy, (b) shares represented by broker non-votes that are present in person or represented by proxy and entitled to vote at the 2021 Annual Meeting and (c) votes to ABSTAIN will be counted for purposes of determining the presence of a quorum at the 2021 Annual Meeting.

What vote is required to approve each item?

The affirmative vote of holders of a majority of the voting power of the shares of stock present or represented by proxy and entitled to vote on the matter is required for (a) each of the Class II nominees named in this Proxy Statement in order to be elected as a Class II director, (b) the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021, (c) the approval of the advisory vote on the frequency of future advisory votes to approve the compensation paid to our named executive officers and (d) the approval of any other matter that may be submitted to a vote of our stockholders.

The inspector of election for the 2021 Annual Meeting shall determine the number of shares of common stock represented at the meeting, the existence of a quorum and the validity and effect of proxies and shall count and tabulate ballots and votes and determine the results thereof. As discussed above, proxies received but marked as abstentions and broker non-votes will be included in the calculation of the number of shares considered to be present at the meeting for purposes of determining a quorum. A “broker non-vote” will occur when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary power with respect to that proposal and has not received instructions from the beneficial owner. The only “routine” proposal on which your broker is entitled to vote your shares if no instructions are received from you is Proposal 2, the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. Broker non-votes will have no effect on the election of

directors in Proposal 1. On Proposal 3 and other matters submitted for a vote, broker non-votes will have no effect in determining whether an item is approved. Abstentions will have the same effect as a vote AGAINST each proposal. If less than a majority of the combined voting power of the outstanding shares of common stock is represented at the 2021 Annual Meeting, a majority of the shares so represented may adjourn the 2021 Annual Meeting from time to time without further notice.

What are the Board of Directors’ recommendations?

As more fully discussed under the section titled “Matters to Come Before the 2021 Annual Meeting,” our board of directors recommends a vote FOR the election of the respective nominees for Class II directors named in the Proxy Statement to serve as directors of the Company until our annual meeting of stockholders in 2024 and until his or her successor has been duly elected and qualified or until his or her earlier resignation, retirement, death, disqualification or removal; FOR the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and for a frequency of 1 YEAR for future advisory votes to approve the compensation paid to the Company’s named executive officers.

Unless contrary instructions are indicated on the enclosed proxy card, all shares represented by valid proxies received pursuant to this solicitation (and which have not been revoked in accordance with the procedures set forth below) will be voted (1) FOR the election of the respective nominees for Class II directors named in this Proxy Statement; (2) FOR the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; (3) for a frequency of 1 YEAR for future advisory votes to approve the compensation paid to the Company's named executive officers and (4) in accordance with the recommendation of our board of directors, FOR or AGAINST all other matters as may properly come before the 2021 Annual Meeting. In the event a stockholder specifies a different choice by means of the enclosed proxy card, such shares will be voted in accordance with the specification made.

How do I vote?

You may vote by following the instructions set forth in the Notice or on your proxy card or, if you are a street name holder (that is, if you hold your shares through a bank, broker or other holder of record), you must vote in accordance with the voting instruction form provided by your bank, broker or other holder of record. You may access the Notice, proxy materials and our Annual Report to stockholders at www.proxyvote.com. If you are a street name holder, the availability of telephone or internet voting will depend upon your bank’s, broker’s or other holder of record’s voting process.

Can I change my vote after I return my proxy card?

Yes. The giving of a proxy does not eliminate the right to vote at the 2021 Annual Meeting should any stockholder giving the proxy so desire. Stockholders have an unconditional right to revoke their proxy at any time prior to the exercise of that proxy by (1) voting at the 2021 Annual Meeting, (2) filing a written revocation or (3) submitting a duly executed proxy bearing a later date than the proxy being revoked with our Secretary at our headquarters.

If your shares of our Class A common stock are held in street name through a broker, bank, or other nominee, you should contact the record holder of your shares regarding how to revoke your proxy or change your vote.

Who pays for costs relating to the proxy materials and annual meeting of stockholders?

The costs of preparing, assembling and mailing the proxy materials, along with the cost of posting the proxy materials on a website, are to be borne by us. In addition to the use of mail, our directors, officers and employees may solicit proxies personally and by telephone, facsimile and other electronic means. They will receive no compensation for such tasks in addition to their regular salaries. We may request banks, brokers and other custodians, nominees and fiduciaries to forward copies of the proxy materials to their principals and to request authority for the execution of proxies. We may reimburse these persons for their expenses in so doing. The costs of holding the 2021 Annual Meeting will also be borne by us.

What does it mean if I received more than one Notice?

If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each Notice to ensure that all of your shares are voted.

Is my vote confidential?

Proxy instructions, ballots and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within 10x Genomics, Inc. or to third parties, except as necessary to meet applicable legal requirements, to allow for the tabulation of votes and certification of the vote, or to facilitate a successful proxy solicitation.

I share an address with another stockholder, and we received only one paper copy of the proxy materials. How may I obtain an additional copy of the proxy materials?

We have adopted a procedure called “householding,” which has been approved by the SEC. Under this procedure, we will deliver only one copy of our Notice of Internet Availability of Proxy Materials, and for those stockholders that received a paper copy of proxy materials in the mail, one copy of our Annual Report to stockholders and this Proxy Statement

, to multiple stockholders who share the same address (if they appear to be members of the same family) unless we have received contrary instructions from an affected stockholder. Stockholders who participate in householding will continue to receive separate proxy cards if they received a paper copy of proxy materials in the mail. This procedure reduces our printing and mailing costs. Upon written or oral request, we will promptly deliver a separate copy of the proxy materials and Annual Report to any stockholder at a shared address to which we delivered a single copy of any of these documents. To receive a separate copy, or, if you are receiving multiple copies, to request that we only send a single copy of next year’s proxy materials and Annual Report, you may contact us as follows:

10x Genomics, Inc.

Attn: Secretary

6230 Stoneridge Mall Road

Pleasanton, CA 94588

(925) 401-7300

Stockholders who hold shares in street name may contact their brokerage firm, bank, broker-dealer or other nominee to request information about householding.

How can I find out the results of the voting at the 2021 Annual Meeting?

Preliminary voting results will be announced at the 2021 Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the 2021 Annual Meeting. If final voting results are not available to us at that time, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an amendment to the Form 8-K to publish the final results.

BOARD OF DIRECTORS AND CORPORATE GOVERNANCE

Director Independence

Our Class A common stock is listed on the Nasdaq Global Select Market (“Nasdaq”). Under the rules of Nasdaq, independent directors must comprise a majority of a listed company’s board of directors within one year of the completion of an offering. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate governance committees be independent. Audit committee members and compensation committee members must also satisfy the independence criteria set forth in Rule 10A-3 and Rule 10C-1, respectively, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Under the rules of Nasdaq, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

To be considered to be independent for purposes of Rule 10A-3 and under the rules of Nasdaq, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2) be an affiliated person of the listed company or any of its subsidiaries.

To be considered independent for purposes of Rule 10C-1 and under the rules of Nasdaq, the board of directors must affirmatively determine that each member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining whether the director has a relationship to the company which is material to that director’s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (i) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the company to such director and (ii) whether such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company.

Our board of directors undertook a review of its composition, the composition of its committees and the independence of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that Sri Kosaraju, Mathai Mammen, Kimberly Popovits, Bryan Roberts, John Stuelpnagel and Shehnaaz Suliman, representing six of our eight directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the rules of Nasdaq.

In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described in the section titled “Certain Relationships and Related Party Transactions.” There are no family relationships among any of our executive officers or directors.

Sections 301.3 and 301.4 of the California Corporations Code

Because our principal executive office is located in California, we must comply with Sections 301.3 and 301.4 of the California Corporations Code. Section 301.3 provides that a publicly held corporation, as defined in the California Corporations Code, that has its principal executive offices in California must have had at least one female director by the close of 2019 and may be required to have as many as three female directors by the close of 2021, depending on the authorized number of directors. Section 301.4 provides that a publicly held corporation, as defined in the California Corporations Code, that has its principal executive offices in California must have had at least one director from an underrepresented community, as defined in Section 301.4, by the close of 2021, and may be required to have as many as three directors from underrepresented communities by the close of 2022, depending on the authorized number of directors. Failure to comply with Sections 301.3 or 301.4 can lead to the imposition of fines. We were in compliance with Section 301.3 for 2020 and we would have been in compliance with Section 301.4 for 2020 had it required us to have had at least one director from an underrepresented community by the close of 2020.

Board of Directors Leadership Structure

Our board of directors is currently chaired by John Stuelpnagel. As a general policy, our board of directors believes that separation of the positions of chairman of our board of directors and Chief Executive Officer and President (a) reinforces the

independence of our board of directors from management, (b) creates an environment that encourages objective oversight of management’s performance and (c) enhances the effectiveness of our board of directors which we believe strengthens the governance structure of our Company as a whole. As such, Serge Saxonov serves as our Chief Executive Officer and Benjamin Hindson serves as our President while John Stuelpnagel serves as the chairman of our board of directors but is not an executive officer. We currently expect and intend the positions of chairman of our board of directors and Chief Executive Officer and President to continue to be held by separate individuals in the future.

Role of Board of Directors in Risk Oversight

Our board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks, including major operational, financial, cybersecurity, legal and reputational risk exposures. The compensation committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee is responsible for overseeing the management of risks relating to accounting matters, cybersecurity and financial reporting. The nominating and corporate governance committee is responsible for overseeing the management of risks associated with the independence of our board of directors and potential conflicts of interest. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected the board of directors’ leadership structure.

Additionally, our board of directors has been engaged with management in monitoring the market and industry developments and other effects of the COVID-19 pandemic, and management is in regular communication with the board of directors about the assessment and management of the significant risks to the Company and COVID-19 pandemic’s impact on our business.

Board of Directors and Committee Meetings

During 2020, our board of directors held six meetings (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (i) the total number of meetings of our board of directors held during the period for which he or she served as a director and (ii) the total number of meetings held by all committees of our board of directors on which he or she served during the periods that he or she served. It is the policy of our board of directors to regularly have separate meeting times for independent directors without management. Although we do not have a formal policy regarding attendance by members of our board of directors at annual meetings of stockholders, we encourage, but do not require, our directors to attend. Six of the members of our board of directors attended last year’s annual meeting.

Board of Directors Committees

Our board of directors has four standing committees: the audit committee; the compensation committee; the mergers and acquisitions committee; and the nominating and corporate governance committee. The audit committee, the compensation committee and the nominating and corporate governance committee are each governed by a charter which satisfies the applicable rules of the SEC and the listing standards of Nasdaq and is available on our website at https://investors.10xgenomics.com/ in the “Governance” section of our Investors webpage. The mergers and acquisitions committee is not governed by a charter. We intend to post any amendments to the charters for each applicable committee on the same website. We believe that the composition of each of the audit committee, the compensation committee and the nominating and corporate governance committee meets the applicable criteria for independence under, and the functioning of these committees complies with the applicable requirements of, the Sarbanes-Oxley Act of 2002, the Nasdaq rules and SEC rules and regulations. We intend to continue to comply with Nasdaq requirements with respect to committee composition of independent directors. Each committee has the composition and responsibilities described below.

Audit Committee

The members of our audit committee are Mr. Kosaraju and Drs. Roberts and Stuelpnagel. Mr. Kosaraju is the chairperson of our audit committee. The composition of our audit committee meets the requirements for independence under the current Nasdaq listing rules and Rule 10A-3 of the Exchange Act. Each member of our audit committee is financially literate and a person with “appropriate accounting or related financial management expertise” under Rule 3.10(2) and 3.21 of the Nasdaq listing rules. In addition, our board of directors has determined that Mr. Kosaraju is an “audit committee financial expert” within the meaning of the SEC rules. This designation does not impose on such directors any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. During 2020, our audit committee held five meetings. Our audit committee is directly responsible for, among other things:

•appointing, retaining, compensating and overseeing the work of our independent registered public accounting firm;

•assessing the independence and performance of our independent registered public accounting firm;

•reviewing with our independent registered public accounting firm the scope and results of the firm’s annual audit of our financial statements;

•overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the interim and annual financial statements that we will file with the SEC;

•pre-approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm;

•reviewing policies and practices related to risk assessment and management;

•reviewing our accounting and financial reporting policies and practices and accounting controls, as well as compliance with legal and regulatory requirements;

•reviewing, overseeing, approving or disapproving any related-person transactions;

•reviewing our cybersecurity readiness and other policies and procedures related to data governance;

•reviewing with our management the scope and results of management’s evaluation of our disclosure controls and procedures and management’s assessment of our internal control over financial reporting, including the related certifications to be included in the periodic reports we will file with the SEC; and

•establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters, or other ethics or compliance issues.

Compensation Committee

The members of our compensation committee are Ms. Popovits and Drs. Roberts and Stuelpnagel. Dr. Stuelpnagel is the chairperson of our compensation committee. Each of Ms. Popovits and Drs. Roberts and Stuelpnagel is a non-employee director, as defined by Rule 16b-3 promulgated under the Exchange Act and meets the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. During 2020, our compensation committee held five meetings. In 2021, our compensation committee engaged Radford, part of the Rewards Solutions practice at Aon, plc, as its independent compensation consultant to assist with its duties, including providing input on the compensation peer group selection, insight into competitive compensation practices and advice on executive compensation programs and decisions. See the section titled “Role of the Compensation Consultant” below for further information. Our compensation committee is responsible for, among other things:

•reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers;

•acting as an administrator of our equity incentive plans;

•reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans;

•reviewing the risks that may arise from our compensation programs; and

•establishing and reviewing general policies relating to compensation and benefits of our employees.

Mergers and Acquisitions Committee

The members of our mergers and acquisitions committee are Mr. Kosaraju and Drs. Shehnaaz and Stuelpnagel. Mr. Kosaraju is the chairperson of our mergers and acquisitions committee. During 2020, our mergers and acquisitions committee held five meetings. The chairperson and members of the mergers and acquisition committee were not compensated for their service on the committee in 2020. Our mergers and acquisitions committee assists the board of directors in reviewing, assessing and, in some circumstances, approving potential mergers, acquisitions, divestitures and other similar strategic transactions and meets on an ad hoc basis.

Nominating and Corporate Governance Committee

The members of our nominating and corporate governance committee are Drs. Mammen and Suliman. Dr. Suliman is the chairperson of our nominating and corporate governance committee. During 2020, our nominating and corporate governance committee held two meetings. Our nominating and corporate governance committee is responsible for, among other things:

•identifying and recommending candidates for membership on our board of directors, including the consideration of nominees submitted by stockholders, and to each of the board’s committees;

•reviewing and recommending our Corporate Governance Guidelines and Policies;

•reviewing proposed waivers of our Code of Business Conduct and Ethics for directors and executive officers;

•overseeing and setting compensation for our directors, including approval of performance-based compensation by reference to corporate goals and objectives resolved by the board of directors from time to time;

•overseeing the process of evaluating the performance of our board of directors; and

•assisting our board of directors on corporate governance matters.

It is the policy of the nominating and corporate governance committee of our board of directors to consider recommendations for candidates to our board of directors from stockholders. The nominating and corporate governance committee will consider candidates recommended by stockholders in the same manner as candidates recommended to the nominating and corporate governance committee from other sources. The nominating and corporate governance committee may propose to our board of directors a candidate recommended or offered for nomination by a stockholder as a nominee for election to our board of directors. In the future, the nominating and corporate governance committee may pay fees to third parties to assist in identifying or evaluating director candidates.

The nominating and corporate governance committee seeks to identify as candidates for director persons with a reputation for and record of integrity and good business judgment and across their nominations, seeks to represent a mix of backgrounds and experiences that will enhance the quality of the deliberations and decisions of our board of directors as a whole. The nominating and corporate governance committee considers the nature of the expertise and experience required for the performance of the duties of a director of the Company, and such matters as the candidate’s relevant business and industry experience, professional background, age, current employment, community service and other board service. Overall, the nominating and corporate governance committee seeks to include a diversity of experience, background, gender, age and ethnicity to ensure that a broad range of views are considered.

In addition, the nominating and corporate governance committee shall take into account all factors it considers appropriate in recommending candidates for election to the board of directors, which may include:

•The current size and composition of our board of directors and the needs of our board of directors and the respective committees of our board of directors.

•Such factors as character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest, other commitments and the like. The nominating and corporate governance committee evaluates these factors, among others, and does not assign any particular weighting or priority to any of these factors.

•Other factors that the nominating and corporate governance committee deems appropriate.

The nominating and corporate governance committee requires the following minimum qualifications to be satisfied by any nominee for a position on our board of directors:

•The highest personal and professional ethics and integrity.

•Proven achievement and competence in the nominee’s field and the ability to exercise sound business judgment.

•Skills that are complementary to those of the existing board of directors.

•The ability to assist and support management and make significant contributions to the Company’s success.

•An understanding of the fiduciary responsibilities that are required of a member of our board of directors and the commitment of time and energy necessary to diligently carry out those responsibilities.

•If the nominating and corporate governance committee determines that an additional or replacement director is required, the nominating and corporate governance committee may take such measures that it considers appropriate in connection with its evaluation of a director candidate, including candidate interviews, inquiry of the person or

persons making the recommendation or nomination, engagement of an outside search firm to gather additional information, or reliance on the knowledge of the members of the nominating and corporate governance committee, our board of directors or management.

Stockholder Recommendations for Nominations to the Board of Directors

A stockholder that wants to recommend a candidate for election to the board of directors should direct the recommendation in writing by letter to 10x Genomics, Inc., attention of the Secretary, at 6230 Stoneridge Mall Road, Pleasanton, California 94588. The recommendation should include the candidate’s name, home and business contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to serve, information regarding any relationships between the candidate and 10x Genomics, Inc. and evidence of the recommending stockholder’s ownership of our stock. Such recommendations must also include a statement from the recommending stockholder in support of the candidate, particularly within the context of the criteria for board membership, as well as personal references.

A stockholder that instead desires to nominate a person directly for election to the board of directors at an annual meeting of the stockholders must meet the deadlines and other requirements set forth in Section 2.03 of our amended and restated bylaws and the rules and regulations of the SEC. Section 2.03 of our amended and restated bylaws requires that a stockholder who seeks to nominate a candidate for director must provide a written notice to the Secretary of the Company not later than the close of business on the ninetieth (90th) day and not earlier than the close of business on the one hundred and twentieth (120th) day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is advanced by more than thirty (30) days, or delayed by more than seventy (70) days, from the anniversary date of the previous year’s meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the one hundred and twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting and the close of business on the tenth (10th) day following the day on which public announcement of the date of such meeting is first made. That notice must state the information required by Section 2.03 of our amended and restated bylaws, and otherwise must comply with applicable federal and state law. Public announcement of an adjournment or postponement of an annual meeting shall not commence a new time period (or extend any time period) for the giving of a stockholder’s notices. The Secretary of the Company will provide a copy of the bylaws upon request in writing from a stockholder. “Public announcement” shall mean disclosure (a) in a press release released by us, provided that such press release is released by us following our customary procedures, is reported by the Dow Jones News Service, Associated Press or comparable national news service, or is generally available on internet news sites, or (b) in a document publicly filed by us with the SEC pursuant to Section 13, 14 or 15(d) of the Exchange Act and the rules and regulations promulgated thereunder.

Stockholders also have the right under our amended and restated bylaws to propose director candidates for consideration by the committee or our board of directors and also directly nominate director candidates, without any action or recommendation on the part of the nominating and corporate governance committee or our board of directors, by following the procedures set forth in the section of this Proxy Statement titled “Proposals of Stockholders for our 2022 Annual Meeting.”

Compensation Committee Interlocks and Insider Participation

During 2020, Ms. Popovits and Drs. Roberts and Stuelpnagel served on our compensation committee. None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our board of directors or compensation committee.

Corporate Governance Guidelines and Code of Business Conduct and Ethics

Our board of directors has adopted Corporate Governance Guidelines. These guidelines address items such as the qualifications and responsibilities of our directors and director candidates and corporate governance policies and standards applicable to us in general. In addition, our board of directors has adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers. The full text of our Corporate Governance Guidelines and our Code of Business Conduct and Ethics is posted on our website at https://investors.10xgenomics.com/ in the “Governance” section of our Investors webpage. We intend to post any amendments to our Corporate Governance Guidelines or Code of Business Conduct and Ethics, and any waivers of our Code of Business Conduct and Ethics for directors and executive officers, on the same website.

Communications with the Board of Directors

Our board of directors believes that management speaks for 10x Genomics, Inc. Individual board members may, from time to time, communicate with various constituencies that are involved with the Company, but it is expected that board members would do this with knowledge of management and, in most instances, only at the request of management.

In cases where stockholders and other interested parties wish to communicate directly with our non-management directors, messages can be sent to our Secretary, at 6230 Stoneridge Mall Road, Pleasanton, California 94588. Our Secretary monitors these communications and will provide a summary of all received messages to the board of directors at each regularly scheduled meeting of the board of directors. Our board of directors generally meets on a quarterly basis. Where the nature of a communication warrants, our Secretary may determine, in his or her judgment, to obtain the more immediate attention of the appropriate committee of the board or non-management director, of independent advisors or of Company management, as our Secretary considers appropriate.

Our Secretary may decide in the exercise of his or her judgment whether a response to any stockholder or interested party communication is necessary.

This procedure for stockholder and other interested party communications with the non-management directors is administered by the Company’s nominating and corporate governance committee. This procedure does not apply to (a) communications to non-management directors from officers or directors of the Company who are stockholders, (b) stockholder proposals submitted pursuant to Rule 14a-8 under the Exchange Act or (c) communications to the audit committee pursuant to the Complaint Procedures for Accounting and Auditing Matters.

DIRECTOR COMPENSATION

The following table provides information regarding compensation earned during the fiscal year ended December 31, 2020 by each non-employee director for his or her service on the board of directors and any committee(s). Our employee directors receive no additional compensation for serving on our board of directors. The compensation paid to Dr. Saxonov for serving as our Chief Executive Officer and Dr. Hindson for serving as our President and Chief Scientific Officer is set forth in the Summary Compensation Table in the Executive Compensation section below.


Name	Fees Earned or Paid in Cash ($)(1)		Stock Option Awards ($)(2)		Total ($)
Sri Kosaraju	$	60,000	$	199,991	$	259,991
Mathai Mammen	45,000		199,991		244,991
Kimberly J. Popovits(3)	32,514		599,991		632,505
Bryan E. Roberts	57,500		199,991		257,491
John R. Stuelpnagel(4)	105,000		199,991		304,991
Shehnaaz Suliman	$	50,000	$	199,991	$	249,991

____________

(1)The fees paid to non-employee directors are described below under the heading “Non-Employee Director Compensation Policy.”

(2)The amounts shown represent the grant date fair value of stock options to purchase shares of our Class A common stock granted to our non-employee directors in fiscal year 2020, as computed in accordance with FASB ASC Topic 718. For a discussion of valuation assumptions used to determine the grant date fair value of the stock options granted to our non-employee directors in fiscal year 2020, see Note 9 of Notes to our Consolidated Financial Statements set forth in our Annual Report on Form 10-K for the year ended December 31, 2020. There can be no assurance that options will be exercised (in which case no value will be realized by the individual) or that the value upon exercise will approximate the fair value as computed in accordance with FASB ASC Topic 718. As of December 31, 2020, the aggregate number of outstanding stock options to purchase shares of our Class A common stock held by each of our non-employee directors who served during fiscal year 2020 included: Mr. Kosaraju, 113,599; Dr. Mammen, 204,432; Ms. Popovits, 14,762; Dr. Roberts, 44,432; Dr. Stuelpnagel, 4,432; and Dr. Suliman, 104,432.

(3)Kimberly J. Popovits was appointed to our board of directors in March 2020.

(4)Mr. Stuelpnagel was granted 150,000 stock options to purchase shares of our Class A common stock on November 18, 2016 (which provided for early exercise), and he exercised all 150,000 of the options on December 31, 2016, with 25,000 of the shares he acquired on exercise remaining subject to repurchase for the exercise price until August 1, 2021 as the corresponding options for which they were exercised were unvested at the time of exercise. In addition, Mr. Stuelpnagel was granted 100,000 stock options to purchase shares of our Class A common stock on November 2, 2018 (which provided for early exercise), and he exercised all 100,000 of the options on December 20, 2018, with 43,750 of the shares he acquired on exercise remaining subject to repurchase for the exercise price until September 1, 2022 as the corresponding options for which they were exercised were unvested at the time of exercise.

Non-Employee Director Compensation Policy

Each of our non-employee directors is entitled to annual compensation in accordance with the following non-employee director compensation policy:

•an annual cash retainer of $40,000, payable quarterly in arrears on a prorated basis;

•the non-employee director serving as chair of our board of directors and each non-employee director serving as a member or chair, as applicable, of the following committees of our board of directors receive the following additional annual retainers, each of which is also payable quarterly in arrears on a prorated basis:

•Chair of the Board of Directors: $40,000

•Audit Committee Chair: $20,000

•Audit Committee Member: $10,000

•Compensation Committee Chair: $15,000

•Compensation Committee Member: $7,500

•Nominating and Corporate Governance Chair: $10,000

•Nominating and Corporate Governance Member: $5,000;

•upon becoming a member of our board of directors, a one-time grant of options having a grant date fair value equal to $400,000 (with the number of options to be granted calculated using the Black-Scholes method or a similar established formula) and an exercise price per share equal to the fair market value (as defined in our 2019 Omnibus Incentive Plan) of a share of Class A common stock on the date of grant, which vests as to one-third of such grant on the first anniversary of the date of grant and thereafter in equal monthly installments for the following two years, subject to the non-employee director continuing in service though each such vesting date; and

•an annual grant of options having a grant date fair market value equal to $200,000 (with the number of options to be granted calculated using the Black-Scholes method or a similar established formula) and an exercise price per share equal to the fair value of a share of Class A common stock on the date of grant, to be granted on the date of our annual meeting of stockholders and which vests monthly over the 12 month period following the date of grant, subject to the non-employee director continuing in service through each such vesting date.

In each case, the options granted will vest in full upon the occurrence of a change in control.

Our directors are not paid any fees for attending meetings. However, our directors are eligible for reimbursement for travel and lodging expenses associated with attendance at board or committee meetings.

MATTERS TO COME BEFORE THE 2021 ANNUAL MEETING

PROPOSAL ONE:

Election of Directors

Board of Directors Composition

Our board of directors currently consists of eight members, with staggered three-year terms, pursuant to our amended and restated certificate of incorporation and amended and restated bylaws. Directors in Class II stand for election at the 2021 Annual Meeting. The terms of office for directors in Class I and Class III will expire at our Annual Meetings of Stockholders to be held in 2023 and 2022, respectively. At the recommendation of our nominating and corporate governance committee, our board of directors proposes that each of the two Class II nominees named below and currently serving as a director in Class II, be elected as a Class II director for a three-year term expiring at our 2024 Annual Meeting of Stockholders, or until such director’s successor is duly elected and qualified, or until their earlier death, resignation, disqualification or removal.

Name

Age

Position

Serge Saxonov

Chief Executive Officer and Director

Benjamin J. Hindson

Chief Scientific Officer, President and Director

John R. Stuelpnagel(1)(2)(3)

Chairman of our Board of Directors

Sri Kosaraju(1)(3)

Director

Mathai Mammen(4)

Director

Kimberly J. Popovits(2)

Director and Director Nominee

Bryan E. Roberts(1)(2)

Director and Director Nominee

Shehnaaz Suliman(3)(4)

Director

____________

(1)Member of our audit committee.

(2)Member of our compensation committee.

(3)Member of our mergers and acquisitions committee.

(4)Member of our nominating and corporate governance committee.

Nominees

Kimberly J. Popovits has served on our board of directors since March 2020. She served as President and Chief Executive Officer of Genomic Health, Inc., a healthcare company, from January 2009, and as Chairman of the Board of Genomic Health, Inc. from March 2012, until the acquisition of Genomic Health, Inc. by Exact Sciences Corporation in November 2019. Ms. Popovits previously served as President and Chief Operating Officer of Genomic Health from February 2002 to January 2009. From November 1987 to February 2002, Ms. Popovits served in various roles at Genentech, Inc., most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, Ms. Popovits served as Division Manager, Southeast Region, for American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. Ms. Popovits has served on the board of directors of Kiniksa Pharmaceuticals, Ltd. since February 2018, and previously served on the board of directors of MyoKardia, Inc. and ZS Pharma Inc. She holds a B.A. in Business from Michigan State University.

We believe that Ms. Popovits is qualified to serve on our board of directors because of her senior management experience in healthcare and biotechnology and her many years of experience with commercial strategy and capability building.

Bryan E. Roberts, Ph.D. has served on our board of directors since November 2013. Dr. Roberts joined Venrock, a venture capital firm, in 1997, where he currently serves as a Partner. Dr. Roberts currently serves as the Chairman of the board of directors of Castlight Health, which he co-founded, as well as a director on the boards of several private companies. Dr. Roberts previously served on the board of directors of athenahealth from 1999 to 2009, XenoPort from 2000 to 2007, Sirna Therapeutics from 2003 to 2007, Vitae Pharmaceuticals from 2001 to 2016, Zeltiq Aesthetics from 2008 to 2016, Ironwood Pharmaceuticals from 2001 to 2016, Hua Medicine from 2010 to 2018 and Achaogen from 2004 to 2019. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts received a B.A. in Chemistry from Dartmouth College and a Ph.D. in Chemistry and Chemical Biology from Harvard University.

We believe that Dr. Roberts is qualified to serve on our board of directors because of his experiences with facilitating the growth of health care, health care IT and biotechnology companies.

Continuing Directors

Serge Saxonov, Ph.D. co-founded 10x Genomics, Inc. and has served as our Chief Executive Officer and on our board of directors since July 2012. Dr. Saxonov also served as our President from July 2012 until October 2012. Prior to co-founding our company, Dr. Saxonov was Vice President of Applications at QuantaLife, a privately-held life sciences company that developed and commercialized a droplet digital polymerase chain reaction platform, from May 2010 to April 2012. Dr. Saxonov was Founding Architect and Director of research and development at 23andMe, a privately held personal genomics and biotechnology company, from June 2006 until May 2010. Dr. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.

We believe that Dr. Saxonov is qualified to serve on our board of directors because of his experience as our co-founder and Chief Executive Officer, industry knowledge, previous experience and extensive academic training.

Benjamin J. Hindson, Ph.D. co-founded 10x Genomics, Inc. in July 2012, has served as our Chief Scientific Officer and President since October 2012 and has served on our board of directors since July 2012. Dr. Hindson served as our President of Technology and Treasurer from July 2012 until October 2012 and as our Secretary from October 2012 until April 2014. Prior to co-founding our company, Dr. Hindson was Co-founder and Chief Scientific Officer of QuantaLife from August 2008 until its sale to Bio-Rad Laboratories in October 2011. From 2002 to 2008, Dr. Hindson served in various positions at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Non-proliferation Program. Dr. Hindson earned his B.Sc. in Chemistry and his Ph.D. in Chemistry from Deakin University, Australia.

We believe that Dr. Hindson is qualified to serve on our board of directors because of his experience as our co-founder, President and Chief Scientific Officer, industry knowledge, previous experience and extensive academic training.

John R. Stuelpnagel, D.V.M. has been Chairman of our board of directors since August 2013. In addition, Dr. Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics from October 2009 to January 2015 when that company was sold to Roche. He was also the Chairman of Sequenta from November 2010 to January 2015 when that company was merged with Adaptive Biotechnologies where he continued as a member of their board of directors from January 2015 to November 2017. Dr. Stuelpnagel has served as the Chairman of Fabric Genomics since August 2009, the Chairman of Inscripta since April 2017, the Chairman of Element Biosciences since September 2017, and a member of the board of directors for Encoded Therapeutics since May 2017. Previously, Dr. Stuelpnagel co-founded Illumina in 1998 where he worked until March 2009. Prior to Illumina, Dr. Stuelpnagel was an associate at CW Group from 1997 to 1998. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

We believe that Dr. Stuelpnagel is qualified to serve on our board of directors because of his experience as a co-founder of life sciences and pharmaceutical companies, previous and current experience serving as a director and executive officer of other life sciences companies and his extensive experience in business.

Sri Kosaraju has served on our board of directors since April 2019. Mr. Kosaraju has served as President and Chief Executive Officer of Inscripta since October 2020. Previously, Mr. Kosaraju served as President of Penumbra from August 2019 to May 2020, Chief Financial Officer from May 2015 to November 2019 and as Head of Strategy from May 2015 to August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC from 1999 to May 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan’s equity capital markets group in 2006, Mr. Kosaraju served in various practice groups at J.P. Morgan, including Equity Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. He received a B.S. from Massachusetts Institute of Technology in 1999.

We believe that Mr. Kosaraju is qualified to serve on our board of directors because of his experiences in finance and the healthcare sector, including serving as an executive at a public healthcare technology company.

Mathai Mammen, M.D., Ph.D. has served on our board of directors since August 2017. Dr. Mammen currently serves as global head, research and development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to joining Janssen Pharmaceutical Companies in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories from March 2016 to June 2017. Prior to Merck, Dr. Mammen led research and development at Theravance, a company he co-founded in

1997 until March 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva and Theravance Biopharma. Dr. Mammen received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry. He received his B.Sc. in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

We believe Dr. Mammen is qualified to serve on our board of directors because of his significant academic training and current and previous experience serving as a director and co-founder of another life sciences company, as well as his operating experience with several life sciences companies.

Shehnaaz Suliman, M.D., M.Phil., M.B.A. has served on our board or directors since August 2019. In addition, Dr. Suliman has served on the board of directors for Ultragenyx Pharmaceutical Inc. since January 2019. She has served as President and Chief Executive Officer of Alector, Inc. since December 2019 and as interim Chief Business Officer of Alector, Inc. since January 2020. Dr. Suliman served as Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc, from July 2017 to March 2019. Prior to her position at Theravance, Dr. Suliman worked for Roche and Genentech, Inc., as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group at Genentech from September 2010 to May 2015 and then as Vice President and Global Therapeutic Area Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc., between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners. She has previously served as a member of the board of directors of Parvus Therapeutics, Inc., a private biopharmaceutical company from October 2017 to July 2019. Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.

We believe that Dr. Suliman is qualified to serve on our board of directors due to her extensive operational experience with global biopharmaceutical and life sciences companies, and particularly her expertise in business development and corporate strategy.

Vote Required

The election of Class II directors requires a majority vote of the voting power of the shares of our common stock present or represented by proxy at the 2021 Annual Meeting and entitled to vote on the subject matter. Under this requirement, in order for a nominee to be elected, the number of shares voted FOR the nominee must exceed the number of shares voted AGAINST or ABSTAIN with respect to such nominee. Broker non-votes will have no effect on this proposal. Abstentions will have the effect of a vote AGAINST the proposal.

RECOMMENDATION OF THE BOARD OF DIRECTORS

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS

A VOTE FOR THE ELECTION OF EACH CLASS II DIRECTOR NOMINEE UNDER PROPOSAL ONE

PROPOSAL TWO:

Ratification of Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2021

Our audit committee has appointed Ernst & Young LLP as our independent registered public accounting firm to audit our financial statements for our fiscal year ending December 31, 2021. Ernst & Young LLP has served as our independent registered public accounting firm since 2015.

Stockholder ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021 is not required by our bylaws or other applicable legal requirements. However, our board of directors is submitting the appointment of Ernst & Young LLP to our stockholders for ratification as a matter of good corporate governance. In the event that this appointment is not ratified by the affirmative vote of a majority of the shares present or by proxy at the 2021 Annual Meeting and entitled to vote, such appointment will be reconsidered by our audit committee and the audit committee may consider whether it should appoint another independent registered public accounting firm. Even if the appointment is ratified, our audit committee, in its sole discretion, may appoint another independent registered public accounting firm if our audit committee believes that such a change would be in the best interests of the Company and its stockholders.

We expect that representatives of Ernst & Young LLP will attend the 2021 Annual Meeting and will have the opportunity to make a statement if they so desire and to respond to appropriate questions.

Fees Paid to the Independent Registered Public Accounting Firm

The following table presents fees for professional audit services and other services rendered to us by Ernst & Young LLP for our fiscal years ended December 31, 2020, 2019 and 2018.


	2018		2019		2020
Audit Fees (1)	$	703,263	$	3,150,917	$	3,908,050
Audit-Related Fees (2)	—		—		—
Tax Fees (3)	—		90,326		403,987
All Other Fees (4)	—		2,000		5,095
	$	703,263	$	3,243,243	$	4,317,132

____________

(1)Audit Fees include billed and unbilled fees for the audit of our consolidated financial statements included in our annual reports on Form 10-K and registration statements on Form S-1 and Form S-3, the review of the unaudited interim financial statements included in our quarterly reports on Form 10-Q, other professional services related to our initial public offering and our September 2020 public offering, various accounting consultations and statutory audit services for certain of our foreign subsidiaries.

(2)Audit-Related Fees consist of fees for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit Fees. There were no Audit-Related Fees incurred in 2020, 2019 or 2018.

(3)Tax Fees include fees in connection with tax consulting and compliance services.

(4)All Other Fees relate to other products and professional services provided by Ernst & Young LLP and include a subscription fee to Ernst & Young LLP’s Atlas Accounting tool incurred in 2019 and 2020. There were no Other Fees incurred in 2018.

Auditor Independence

In 2020, there were no other professional services provided by Ernst & Young LLP that would have required our audit committee to consider their compatibility with maintaining the independence of Ernst & Young LLP.

Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm

Our audit committee has established a policy governing our use of the services of our independent registered public accounting firm. Under the policy, our audit committee is required to pre-approve all audit and permissible non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair such

accounting firm’s independence. All fees paid to Ernst & Young LLP for our fiscal years ended December 31, 2020, 2019 and 2018 were pre-approved by our audit committee.

Vote Required

The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021 requires the affirmative vote (i.e., a FOR vote) of a majority of the voting power of the shares of our common stock present or represented by proxy at the 2021 Annual Meeting and entitled to vote on the subject matter. A vote to ABSTAIN will have the same effect as a vote AGAINST the proposal. This is the only proposal on which your broker is entitled to vote your shares if no instructions are received from you.

RECOMMENDATION OF THE BOARD OF DIRECTORS

THE BOARD OF DIRECTORS UNANIMOUSLY

RECOMMENDS A VOTE FOR THE RATIFICATION OF ERNST & YOUNG LLP

AS THE COMPANY’S INDEPENDENT PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2021 UNDER PROPOSAL TWO

PROPOSAL THREE:

Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation

As part of the commitment of our board of directors to excellence in governance, and as required by Section 14A of the Exchange Act, our board of directors will provide stockholders with an opportunity to approve, on a non-binding, advisory basis, the compensation of our named executive officers, commonly known as a “say on pay” proposal, next year at our 2022 Annual Meeting. As more fully described in the section of this Proxy Statement titled “Executive Compensation,” including “Compensation Discussion and Analysis” and related compensation tables, our executive compensation program is designed to attract, retain, and motivate talented individuals with the executive experience and leadership skills necessary for us to increase stockholder value.

Section 14A of the Exchange Act also requires us to submit a non-binding, advisory resolution, commonly known as a “say on frequency” proposal, to stockholders at least once every six years to determine whether non-binding, advisory votes to approve the compensation of our named executive officers, should be held every one, two or three years. This is the first year we have submitted a “say on frequency” proposal to our stockholders. Under this proposal, you may vote on whether you prefer to have a “say on pay” vote every year, every two years or every three years, or abstain, in accordance with the following resolution:

“RESOLVED, that the option of 1 YEAR, 2 YEARS, or 3 YEARS that receives the majority of affirmative votes for this resolution will be determined to be the preferred frequency with which 10x Genomics, Inc. is to hold a stockholder vote to approve on a non-binding, advisory basis the compensation of the Company’s named executive officers, as disclosed in this Proxy Statement, including the "Compensation Discussion and Analysis" compensation tables and related narrative discussion.

After careful consideration, our board of directors has determined that an annual advisory vote to approve the compensation of our named executive officers will allow our stockholders to provide timely and direct input on our executive compensation philosophy, policies and practices as disclosed in the Proxy Statement each year. The board of directors believes that an annual vote is therefore consistent with our efforts to engage in an ongoing dialogue with our stockholders on executive compensation and corporate governance matters.

This vote is advisory, and therefore not binding on the Company, our board of directors or the compensation committee. However, our board of directors and the compensation committee value the opinions of our stockholders and intend to take into account the outcome of the vote when considering the frequency of holding future non-binding, advisory votes to approve the compensation of our named executive officers.

Vote Required

Stockholders will be able to specify one of four choices on their proxy card or voting instruction for this proposal: 1 YEAR, 2 YEARS, 3 YEARS, or ABSTAIN. Approval of the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers requires the affirmative vote of a majority of the voting power of the shares of our common stock present or represented by proxy at the 2021 Annual Meeting and entitled to vote on the subject matter (i.e., affirmative votes for one of the three options (1 YEAR, 2 YEARS, or 3 YEARS) must exceed the votes for the other options and abstentions combined). Broker non-votes will have no effect in determining whether a frequency is approved. Abstentions will have the same effect as a vote AGAINST an option. Because stockholders have several voting choices with respect to this proposal, it is possible that no single option will receive a majority vote. In light of the foregoing, the board of directors will consider the outcome of the vote when determining the frequency of future non-binding votes on executive compensation.

RECOMMENDATION OF THE BOARD OF DIRECTORS

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS

A VOTE FOR "1 YEAR" ON A NON-BINDING, ADVISORY BASIS OF THE

FREQUENCY OF FUTURE NON BINDING, ADVISORY VOTES TO APPROVE THE

COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS UNDER PROPOSAL THREE

AUDIT COMMITTEE REPORT

Pursuant to rules adopted by the SEC designed to improve disclosures related to the functioning of corporate audit committees and to enhance the reliability and credibility of financial statements of public companies, the audit committee of our board of directors submits the report below. The material in this report is not “soliciting material,” is not be deemed “filed” with the SEC, and is not to be incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that the Company specifically incorporates it by reference in such filing.

Audit Committee Report to Stockholders

The audit committee of the board of directors is responsible for providing independent, objective oversight of the Company’s accounting functions and internal controls. The audit committee is composed of three directors, each of whom is independent as defined under the rules of Nasdaq. Our board of directors has determined that each member of the audit committee is independent and that Mr. Kosaraju qualifies as an “audit committee financial expert” under the SEC rules. The audit committee operates under a written charter approved by the board of directors and held five meetings in fiscal year 2020. A copy of the charter is available on the Company’s website at https://investors.10xgenomics.com/ in the “Governance” section of the Investors webpage.

Management is responsible for the Company’s internal controls over financial reporting, disclosure controls and procedures and the financial reporting process. Ernst & Young LLP is responsible for performing an independent audit of the Company’s financial statements in accordance with Public Company Accounting Oversight Board (“PCAOB”) standards and to issue reports thereon. The audit committee’s responsibility is to monitor and oversee these processes. The audit committee has established a mechanism to receive, retain and process complaints on auditing, accounting and internal control issues, including the confidential, anonymous submission by employees, vendors, customers and others of concerns on questionable accounting and auditing matters.

In connection with these responsibilities, the audit committee met with management and Ernst & Young LLP to review and discuss the December 31, 2020 audited financial statements. The audit committee also discussed with Ernst & Young LLP the matters required to be discussed by the applicable requirements of the PCAOB and the SEC. In addition, the audit committee received the written disclosures from Ernst & Young LLP required by applicable requirements of the PCAOB regarding Ernst & Young LLP’s communications with the audit committee concerning independence, and the audit committee has discussed with Ernst & Young LLP its independence from the Company and its management.

Based on the audit committee’s discussions with management and Ernst & Young LLP, and the audit committee’s review of the representations of management and Ernst & Young LLP, the audit committee recommended that the board of directors include the audited financial statements in the Company’s Annual Report on Form 10-K for fiscal year 2020 filed with the SEC.

The audit committee also has appointed, subject to stockholder ratification on an advisory basis, Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

Respectfully submitted,

THE AUDIT COMMITTEE OF

THE BOARD OF DIRECTORS OF 10X GENOMICS, INC.

Sri Kosaraju, Chairman

Bryan E. Roberts

John R. Stuelpnagel

COMPENSATION COMMITTEE REPORT

The Compensation Committee has reviewed and discussed with management the disclosures contained in the following “Compensation Discussion and Analysis.” Based on this review and discussion, the Compensation Committee recommended to the board of directors that the section titled “Compensation Discussion and Analysis” be included in this Proxy Statement for the 2021 Annual Meeting.

Respectfully submitted,

THE COMPENSATION COMMITTEE OF

THE BOARD OF DIRECTORS OF 10X GENOMICS, INC.

John R. Stuelpnagel, Chairman

Kimberly J. Popovits

Bryan E. Roberts

EXECUTIVE OFFICERS

The following table sets forth certain information about our executive officers and their respective ages as of April 23, 2021. Officers are elected by the board of directors to hold office until their successors are elected and qualified.

Name

Age

Position

Serge Saxonov

Chief Executive Officer and Director

Justin J. McAnear

Chief Financial Officer

Benjamin J. Hindson

Chief Scientific Officer, President and Director

Bradford J. Crutchfield

Chief Commercial Officer

Ruth De Backer

Chief Business Officer

Eric S. Whitaker

General Counsel

Jean M. Philibert

Chief People Officer

For the biographies of Drs. Hindson and Saxonov, see “Matters to Come Before the 2021 Annual Meeting—Proposal One—Election of Directors—Continuing Directors.”

Justin J. McAnear has served as our Chief Financial Officer since October 2018. From August 2015 to October 2018, Mr. McAnear was the Vice President of Worldwide Finance and Operations at Tesla. From September 2013 to August 2015, Mr. McAnear served as a Finance Director at Apple in Corporate FP&A and Worldwide Operations and from February 2011 to September 2013, Mr. McAnear served as a Senior Finance Manager in Worldwide Operations. Mr. McAnear began his corporate finance career at Johnson & Johnson in August 2006 and left in February 2011. Mr. McAnear served over nine years in the U.S. Navy as an aviator and is a graduate of the U.S. Naval Academy in Annapolis, Maryland, where he earned his B.S. degree in Systems Engineering. He also holds an M.B.A. in Finance from the University of San Diego.

Bradford J. Crutchfield has served as our Chief Commercial Officer since February 2017. From June 2015 to February 2017, Mr. Crutchfield served as Qiagen’s senior vice president, life sciences business area. Prior to that, from October 2014 to April 2015, Mr. Crutchfield served as vice president and general manager, Europe, Middle East & Africa, for Illumina. From 1985 to 2014, Mr. Crutchfield held positions with Bio-Rad Laboratories including executive vice president and president of the Life Science Group. From June 2013 until October 2014, he was a director of Nanostring Technologies. Mr. Crutchfield holds a B.S. in Physiology from the University of California, Davis.

Ruth De Backer has served as Chief Business Officer of 10x Genomics since 2020, bringing extensive experience in strategy and corporate development in the pharma and medical industries to the company. Prior to 10x Genomics, Ms. De Backer spent nearly 20 years at McKinsey & Company and rose to partner where she led McKinsey's Strategy & Corporate Finance Practice in Pharmaceuticals & Medical Products. In her tenure at McKinsey, she advised clients on a range of areas including growth strategies, capital allocation, and transactions. Ms. De Backer holds a Licentiate in Law from University of Ghent, Belgium and a LL.M. from New York University.

Eric S. Whitaker has served as our General Counsel since July 2017. Prior to joining our company, Mr. Whitaker served as the Chief Legal Officer of Nutanix from September 2014 to May 2017, the Chief Legal Officer of SanDisk from January 2013 to September 2014, and General Counsel of Tesla from October 2010 to November 2012. Prior to these roles, Mr. Whitaker served as General Counsel for a number of technology companies since 1999. Mr. Whitaker also worked as an attorney at Latham & Watkins LLP. Mr. Whitaker holds a J.D. from Stanford Law School and a B.A. in Politics from Princeton University.

Jean M. Philibert has served as our Chief People Officer since April 2018. From January 2016 until March 2018, Ms. Philibert served as Senior Vice President of Human Resources at Analog Devices. From December 2014 to December 2015, Ms. Philibert served as the Chief People Officer at KIXEYE. In 19999, Ms. Philibert joined EMC and served as a Senior Director of Human Resources until November 2014. She earned a M.S. in Industrial Relations and Human Resources from Loyola University and a B.A. in French and Art History from the University of Iowa.

EXECUTIVE COMPENSATION

This section describes the compensation program for our named executive officers (“NEOs”), including “Compensation Discussion and Analysis,” executive compensation tables and other information.

Compensation Discussion and Analysis

This discussion and analysis summarizes the material components of our executive compensation program and our compensation policies, practices and material compensation decisions for our named executive officers. Pursuant to U.S. federal securities laws, those who served as our Chief Executive Officer, Chief Financial Officer and the three other most highly compensated executive officers for the fiscal year ending December 31, 2020 are our named executive officers. Our named executive officers for 2020 are:


Serge Saxonov			Chief Executive Officer
Justin J. McAnear			Chief Financial Officer
Benjamin J. Hindson			President and Chief Scientific Officer
Bradford J. Crutchfield			Chief Commercial Officer
Ruth De Backer			Chief Business Officer

Compensation Philosophy

Our mission is to accelerate the mastery of biology to advance human health, and achieving this requires an exceptional team of individuals bringing diverse skills together to find innovative solutions to difficult problems. Our various compensation programs are based upon the following guiding principles which enable us to build and maintain our team.

•Performance: Final pay outcomes are designed to be tied to individual, team and overall company performance, with the weighting of those factors dependent on the individual’s role and level of responsibility. Incentives in the form of bonuses and equity compensation are designed to align the interests of our executive officers more closely with those of our shareholders and to motivate such executive officers to increase shareholder value by improving corporate performance and profitability.

•Consistency: Annual total target compensation (consisting of annual base salary, annual target bonus and the annual target equity award) is intended to be consistent with competitive opportunities available to the exceptional people we seek to attract and retain.

•Fairness: Our programs are designed to be equitable across similarly situated employees, encouraging employee motivation and enabling collaboration necessary to solve new problems.

Compensation Setting Process

Role of our Compensation Committee

Our compensation committee administers our executive compensation program, making final decisions on program design and compensation changes for our executive officers. Under its charter, our compensation committee reviews, determines, approves, or makes recommendations to our board of directors regarding executive officer compensation, board compensation, and compensation under our equity incentive plans. See the sections titled “Board of Directors Committees” and “Compensation Committee” beginning on page 8 for more information about the compensation committee and how to access its charter.

Role of Management

Our Chief Executive Officer, General Counsel, Chief Financial Officer and Vice President of Human Resources provide our compensation committee with information on company and individual performance, competitive practices and perspectives and recommendations on compensation matters. No executive officer participates in deliberations regarding his or her own pay.

In reviewing compensation for our executive officers other than the Chief Executive Officer, including the determination of equity awards to be granted to such executive officers, our compensation committee solicits input from our Chief Executive Officer on each executive officer’s performance, strategic contributions, ability, job complexity, responsibilities and competitive opportunities. Our compensation committee values our Chief Executive Officer’s perspective and input on each executive officer’s performance and contributions to the Company, and it is an important factor in the compensation committee’s final determinations.

Role of the Compensation Consultant

Our compensation committee has the authority to engage its own advisors in carrying out its responsibilities. In 2021, our compensation committee engaged Radford, part of the Rewards Solutions practice at Aon plc, as its independent compensation consultant to assist with its duties, including providing input on the compensation peer group selection, insight into competitive compensation practices and advice on executive compensation programs and decisions. In 2020, Radford performed services for the Company including subscriptions to broad-based compensation survey data, and was paid fees for these services totaling approximately $127,000. In addition, Radford affiliates (Aon plc and its related entities) performed insurance advisory services, risk management consulting and insurance brokerage services for us during 2020, for which we paid approximately $1,864,000. Additional insurance premiums and related fees were paid to Aon plc and passed through to insurance companies not affiliated with Aon plc. Our compensation committee reviewed these services and considered the independence of Radford in light of SEC rules regarding conflicts of interest involving compensation consultants and Nasdaq listing standards regarding compensation consultant independence. Our compensation committee considered the following six factors, as well as other factors it deemed relevant, in order to make its determination: (i) the provision of other services to us by Radford and the Radford affiliates described above; (ii) the amount of fees Radford received from us, as a percentage of its total revenue; (iii) the policies and procedures of Radford that are designed to prevent conflicts of interest; (iv) the lack of any business or personal relationships of the Radford consultants with any member of our compensation committee; (v) the lack of any 10x Genomics, Inc. stock owned by the Radford consultants performing services for our compensation committee; and (vi) the lack of any business or personal relationships between the Radford consultants or Radford itself and any of our executive officers. Based on its review, our compensation committee determined that Radford was independent, and that Radford’s services did not raise any conflicts of interest.

Use of Competitive Data

Our compensation committee uses data on competitive compensation practices to assist with the compensation decisions for our executive officers. In 2020, our compensation committee reviewed data from a peer group of companies selected to be representative of 10x Genomics, Inc. in terms of labor market, financial profile and business type. The companies selected generally had a focus on genetic testing, life science software, or enterprise software. Selected companies generally had annual revenues in the range of 0.8 times to 2.4 times the trailing 12 months revenues of 10x Genomics, Inc., and a market capitalization of 0.7 times to 1.8 times that of 10x Genomics, Inc. The following are the companies selected in that list:


ACADIA Pharmaceuticals	Coupa Software	Paylocity Holding
Adaptive Biotechnologies	Exact Sciences	Penumbra
Alnylam Pharmaceuticals	Guardant Health	Sarepta Therapeutics
Alteryx	Invitae	Teladoc Health
Anaplan	Natera	Zscaler
Avalara

At the time the peer companies were selected, 10x Genomics, Inc. was positioned at the 22nd percentile of trailing revenues, at the 81st percentile of revenue growth and at the 60th percentile of market capitalization.

Data for these companies was collected from publicly available filings and from the Radford surveys. The data was used as a lens to understand competitive opportunities for our employees. On an overall basis, annual target total compensation (consisting of annual base salary, target annual bonus and the target annual equity award) for our named executive officers in 2020 was set at levels that generally fell between 60th and 75th percentiles of our peer group and size appropriate general industry survey data. Though its analysis of peer group and other competitive market data informs its decisions, in keeping with our guiding principles of consistency and fairness, our compensation committee also applies its subjective judgment in determining the pay levels of individual executive officers in order to account for each individual’s performance and to align with shareholder interests. The additional factors considered in making individual compensation decisions include input from

our Chief Executive Officer, company performance, individual performance and experience, individual skills and expertise, each executive officer’s role and our retention and incentive objectives.

Compensation Program Design

The 2020 executive compensation program was designed with our guiding principles in mind, including the alignment of incentives for our named executive officers with the long-term interests of our shareholders. Our 2020 compensation program was composed of three primary elements: base salary, annual cash bonus opportunities and equity awards composed of stock options.

•Base Salary: Provides our named executive officers with fixed compensation. We believe the salaries for our named executive officers are set low relative to competitive practices. In April 2020, our compensation committee reviewed the base salaries of our named executive officers by comparing them to named executive officer salaries within our peer group utilizing publicly available filings and the Radford surveys discussed above. Such comparisons revealed that our named executive officers’ salaries are below the market median. However, due to the uncertainty created at that time by the unfolding COVID-19 pandemic, management recommended, and our compensation committee approved, making no adjustments to the salary levels then in effect for our executive officers.

•Annual Incentive Plan: We maintain an Annual Incentive Plan (“AIP”) for all employees, including our named executive officers. Comparisons to annual incentive plans of companies in our peer group, through publicly available filings and the Radford surveys discussed above, revealed that our named executive officers are provided with target award opportunities in the AIP that are below typical competitive practices. No cash bonuses were paid to our named executive officers for 2020 performance.

•Equity Incentives: Our named executive officers are eligible for equity awards as part of our executive compensation program. In 2020, our compensation committee granted equity awards for our named executive officers entirely in the form of stock options. Stock options link the strategic and day-to-day actions of our executive officers directly to shareholder interests by motivating such executive officers to increase shareholder value by improving corporate performance and profitability. Comparisons to equity awards by companies in our peer group, through publicly available filings and the Radford surveys discussed above, revealed that our executive officers are provided equity awards above typical competitive practices. We overemphasize equity opportunities relative to cash opportunities in order to motivate our executives to focus on long-term value creation and accordingly have underweighted both base salary and annual target bonus as components of our annual total target compensation.

Shareholders will have the opportunity to approve, on a non-binding, advisory basis, the compensation of our named executive officers next year at our 2022 Annual Meeting, in accordance with Section 14A of the Exchange Act.

Compensation Elements

Base Salary

Base salaries for our named executive officers provide a fixed minimum level of compensation for services rendered during the year. Salary levels are reviewed annually, or upon significant changes in such named executive officer’s role and responsibilities and, with respect to our named executive officers other than the Chief Executive Officer, in consultation with our Chief Executive Officer. There is no specific formula applied to determine salary adjustments. Any adjustments are designed to reflect (a) the skills, knowledge and responsibilities required of each named executive officer, (b) the performance of the Company as a whole, as well as (c) the competitive labor market conditions.

Effective January 1, 2020, our compensation committee decided that Mr. Crutchfield would participate in the Annual Incentive Plan (discussed below) instead of a cash incentive plan based on total shippable bookings (a “sales incentive plan”) that he had participated in previously, in order to align his incentives with those of the other executive officers. As part of this change, his annual target bonus opportunity was reduced from 40% of base salary to 28% of base salary. In order to partially offset this reduction in annual target bonus opportunity, Mr. Crutchfield’s base salary was increased from $330,000 to $350,000.

The base salary for Ms. De Backer was set at an annualized rate of $350,000, effective upon the commencement of her employment on April 27, 2020. This salary, as part of Ms. De Backer’s overall compensation package, was the result of a negotiation between Ms. De Backer and the Company. The negotiation was led by our Chief Executive Officer, in consultation with our compensation committee, and was approved by our compensation committee.

As discussed above, in light of the significant uncertainties created by the COVID-19 pandemic, in April 2020, management recommended, and our compensation committee approved, the decision not to make any adjustments to base salaries for our named executive officers. This decision was not a reflection of our compensation committee’s assessment of the performance of the named executive officers or of the company.

The annualized base salaries of our named executive officers as of December 31, 2020 compared to December 31, 2019 were:


Named Executive Officer	Annual Base Salary as of December 31, 2019	Annual Base Salary as of December 31, 2020	Percentage Increase
Dr. Saxonov	$400,000	$400,000	—%
Mr. McAnear	$330,000	$330,000	—%
Mr. Crutchfield	$330,000	$350,000	6%
Dr. Hindson	$350,000	$350,000	—%
Ms. De Backer	N/A	$350,000	N/A

Annual Incentive Plan

10x Genomics, Inc. maintains the AIP to provide employees, including our named executive officers, with incentives reflecting annual Company performance and individual contributions. The target award opportunity and the weighting between Company and individual performance reflect the role of each individual participant. For fiscal year 2020, the compensation committee increased the annual bonus award targets for named executive officers under the AIP in order to move the AIP closer to competitive cash incentive opportunities. The AIP targets were increased by 5% of base salary, resulting in a change in the target AIP opportunity from 39% to 44% for Dr. Saxonov, and a change from 23% to 28% for the other named executive officers who were employed by us in 2019. Prior to 2020, Mr. Crutchfield participated in a sales incentive plan with a target bonus opportunity of 40% of base salary. Effective January 1, 2020, he no longer participated in such sales incentive plan and instead participated in the AIP at the same target (28% of base salary) as other named executives. In February 2020, our compensation committee approved the following target incentive opportunities and performance weightings for our named executive officers:


Named Executive Officer	Target AIP Opportunity (% of Base Salary)	10x Genomics, Inc. Performance Weighting	Individual Performance Weighting	Actual Bonus Payout
Dr. Saxonov	44%	100%	—%	—%
Mr. McAnear	28%	75%	25%	—%
Mr. Crutchfield	28%	75%	25%	—%
Dr. Hindson	28%	75%	25%	—%
Ms. De Backer	28%	75%	25%	—%

Our AIP contains (a) a funding formula, which must be attained before any individual bonus can be paid, and (b) a Company performance factor, which determines the portion of the bonus that is tied to the performance of 10x Genomics, Inc. as measured by our annual performance goals. This method is designed to create a link between our executive compensation and 10x Genomics, Inc.’s annual performance and to reward our named executive officers when we meet our annual performance goals. In February 2020, our compensation committee decided to set both the funding formula and Company performance factor to be the same. Both would equal to 100% if our 2020 revenue target had been met and would be zero otherwise. Due to the impact of the COVID-19 pandemic this target was not met, and therefore no bonus payouts were made to our named executive officers for 2020.

Sign-On and Relocation Bonus

As part of our negotiation with Ms. De Backer, we agreed to a sign-on/relocation bonus of $100,000. The purpose of this bonus was to provide an inducement to join 10x Genomics and to mitigate the costs of moving to the San Francisco Bay Area.

Equity Awards

Equity awards provide (a) ongoing incentives tied to the creation of shareholder value as reflected in the Company’s stock price and (b) retention incentives to motivate our employees through multi-year vesting schedules. For our named executive officers, equity incentives provide the majority of their expected compensation value.

The 2020 equity awards granted to our named executive officers other than Ms. De Backer were comprised entirely of stock options. Stock options are intended to motivate our named executive officers to drive growth and increase shareholder value by only having value if the price of our stock increases. The stock options granted in 2020 to our named executive officers other than Ms. De Backer vest monthly over 4 years at a rate of 1/48th per month and are designed to incentivize retention. 2020 represented the first cycle of our annual compensation review to occur as a public company. Because the circumstances and opportunities inherent in pre-IPO equity awards are materially different from those of a publicly traded company, our compensation committee did not consider the size of the equity awards made 2019 when determining the grants to named executive officers in 2020. As described below, Ms. De Backer's new hire stock option and RSU grants begin vesting on April 27, 2021 (the one year anniversary of the commencement of her employment and May 21, 2021, respectively.

We do not have an established set of criteria for granting equity awards. Instead, our compensation committee has exercised its judgment and discretion, in consultation with our Chief Executive Officer (other than with respect to his own equity award), and considered factors including the role and responsibility of each named executive officer, the outstanding equity held by each named executive officer and the extent to which it has vested, cash compensation opportunity and individual performance.

The equity awards granted to our named executive officers other than Ms. De Backer in 2020 are detailed below:


Named Executive Officer	Number of Securities Underlying Options (#)	Grant Date Fair Value ($)
Dr. Saxonov	235,733	10,227,724
Mr. McAnear	90,667	3,933,816
Mr. Crutchfield	90,667	3,933,649
Dr. Hindson	136,000	5,900,537

Because Ms. De Backer was hired in 2020, her 2020 equity award was agreed to as part of our negotiation of the offer for her to join 10x Genomics. The award was targeted to be comprised of approximately 50% RSUs and 50% stock options. The offer provided for a number of RSUs equal to $3,500,000 divided by the average closing price of our stock over the first 20 trading days of the month following the month of hire. The RSUs vest 25% on May 21, 2021, and then 1/16th quarterly thereafter. The offer provided for a number of stock options equal to $3,500,000 divided by 40% of the average closing price of our stock over the first 20 trading days of the month following the month of hire. The stock options vest 25% on April 27, 2021, and then 1/48th monthly thereafter. Due to appreciation in the stock price between the period used to determine the numbers of shares in the respective awards and the stock price on the date the awards were formally approved by our compensation committee, as well as differences in the option value agreed to in the offer and the valuation method used to determine the grant date fair value of options under GAAP, the grant date fair value reported in the Summary Compensation Table exceeds the target total value of $7,000,000 specified in the offer.

No Special Retirement, Health or Welfare Benefits

Our named executive officers are eligible to participate in our employee benefit programs on the same basis as our other salaried employees. We maintain a tax-qualified retirement plan (“401(k) Plan”) that provides eligible employees with an opportunity to save for retirement on a tax-advantaged basis. Eligible employees are able to participate in the 401(k) Plan as of the first day of the month following the date they meet the 401(k) Plan’s eligibility requirements, and participants are able to defer up to 75% of their eligible compensation subject to applicable annual tax limits. All participants’ interests in their deferrals are 100% vested when contributed. We have not made any matching or profit sharing contributions to our 401(k) plan to date.

Our health and welfare benefits include medical, dental and vision benefits, disability insurance, basic life insurance coverage, and accidental death and dismemberment insurance. We design our employee benefits programs to be affordable and competitive in relation to the market and compliant with applicable laws and practices. We adjust our employee benefits programs as needed based upon changes in applicable laws and market practices.

Other Personal Benefits

During 2020, our compensation committee determined that it was appropriate and in the interest of the Company to grant both Dr. Hindson and Dr. Saxonov a one-time cash bonus of $125,000, which is equal to the amount of each of Dr. Hindson and Dr. Saxonov’s filing fees under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (the “HSR Act”) and a one-time income tax “gross-up” bonus in connection with each such bonus, in the amount of $126,512. The value of company stock owned by each exceeded the HSR size-of-transaction threshold limits set forth in the HSR regulations and each was required to make a HSR filing in 2020 to increase their respective stock ownership levels in the company. The compensation committee determined that it was appropriate for the company to reimburse each for this expense. We do not generally provide perquisites or other personal benefits to our named executive officers, except in limited situations where we believe it is appropriate.

Severance Arrangements

We believe that reasonable and appropriate severance benefits are necessary in order to be competitive in our executive attraction and retention efforts. See the section titled “Potential Payments upon Termination or Change in Control or Termination of Employment” beginning on page 35 for a more detailed description of these benefits.

Change in Control Severance Policy

Effective July 30, 2020, our compensation committee adopted the 10x Genomics, Inc. Severance Policy, which is intended to provide severance pay and other benefits to certain eligible employees (including our NEOs) and other service providers of the Company and its subsidiaries and affiliates in the event of certain terminations of employment in connection with a “change in control” (as defined in the Severance Policy). The Severance Policy also provides accelerated vesting of certain outstanding stock options and restricted stock units held by eligible employees and other service providers.

The Severance Policy became effective upon its adoption by our compensation committee and will continue in effect until December 31, 2024. The term of the Severance Policy will automatically be extended for one additional year at the end of the initial term and then again after each successive one-year period thereafter, unless it is terminated or amended by our compensation committee (the plan administrator).

The following individuals are eligible to participate in the Severance Policy:

•An employee who is classified by the Company as a regular full-time salaried or hourly employee of the Company or any of its subsidiaries or affiliates and is primarily employed in the United States.

•An employee of the Company or any of its subsidiaries or affiliates who is not a U.S. employee and who holds or is granted stock options or restricted stock units.

•A consultant or advisor to the Company or any of its subsidiaries or affiliates (excluding any non-employee director of the Company) who holds or is granted stock options or restricted stock units.

The Severance Policy provides certain payments and benefits upon a “qualifying termination,” which is defined as follows: (i) (A) with respect to any participant who is a U.S. employee or non-U.S. employee, a termination of the participant’s employment by the Company or the subsidiary or affiliate thereof by which the participant is employed without “cause” or by the participant for “good reason” (as such terms are defined in the Severance Policy) or (B) with respect to any participant who is a consultant or advisor, a termination of the participant’s service with the Company or the subsidiary or affiliate thereof by which the participant is engaged for any reason other than the expiration of the term of such participant’s consulting or advisory agreement (or other applicable service agreement) with the Company or such subsidiary or affiliate and (ii) in all cases, such termination occurs during the period starting on the effective date of a change in control and ending on the date that is 24 months after a change in control.

Under the Severance Policy, if a U.S. employee incurs a qualifying termination, then the U.S. employee will be entitled to receive the following severance payments and benefits, subject to such employee’s timely execution, delivery and non-revocation of a separation agreement and release of claims in favor of the Company and its affiliates and compliance with restrictive covenants set forth in the separation and release agreement (or any other agreement to which such participant is a party with the Company or any of its subsidiaries or affiliates):

•Continued payment of annual base salary for a period of six months following the employee’s termination date, payable in equal installment in accordance with the Company’s normal payroll practices; and

•In the event the employee timely elects under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) to continue health care coverage under the Company’s group health plans, such employee will be required to timely pay the premiums for coverage of such employee and such employee’s eligible dependents, but a portion of such premiums will be paid or reimbursed by the Company for six months following the employee’s termination date (beginning on the date such premiums begin) such that the employee will continue to pay the same amount of monthly premiums as in effect for an active employee with the same coverage.

In addition, under the Severance Policy, if a participant (including a U.S. employee, non-U.S. employee, or consultant or advisor) remains employed or in service with the Company through the date on which a change in control occurs, any outstanding stock options or restricted stock units then held by the participant will be treated as follows:

•If such equity award is assumed, converted or replaced by the surviving corporation (including the Company if the Company is the surviving corporation) or its parent with equity or equity-based awards having an equivalent value and vesting schedule to those applicable to such equity award immediately prior to the change in control, such award as so-assumed, converted or replaced, as applicable, will remain eligible to vest and become exercisable in accordance with its terms; provided that, in the event of a participant’s qualifying termination (and subject to the participant’s timely execution, delivery and non-revocation of a separation agreement and release of claims in favor of the Company and its affiliates and compliance with restrictive covenants set forth in the separation and release agreement (or any other agreement to which such participant is a party with the Company or any of its subsidiaries or affiliates)), such award will vest and any restrictions thereon will lapse as to 100% of the then-unvested portion of the award (provided that, unless the applicable award agreement provides for different treatment upon a qualifying termination following a change in control, with respect to awards that would otherwise vest upon satisfaction of performance criteria, all applicable performance criteria will be deemed to have been achieved at target levels).

•If such equity award is not so assumed, converted or replaced in connection with the change in control, then immediately on the effective date of the change in control, such equity award will vest and any restrictions thereon will lapse as to 100% of the then-unvested portion of the equity award (provided that, unless the applicable award agreement provides for different treatment upon a change in control, with respect to equity awards that would otherwise vest upon satisfaction of performance criteria, all applicable performance criteria will be deemed to have been achieved at target levels).

The Severance Policy provides that no U.S. employee is eligible to receive any other severance payments or severance benefits under any other severance plan, policy or program of the Company, or pursuant to the terms of any employment or other agreement with the Company, as may be in effect from time to time. Any severance payments or severance benefits payable to a U.S. employee under the Severance Policy are in lieu of any severance payments or benefits to which such U.S. employee may otherwise have been entitled to pursuant to any other severance plan, policy or program of the Company, or pursuant to the terms of any employment or other agreement with the Company. Participants are also eligible for any benefits provided upon termination pursuant to the 2012 Plan, the 2019 Plan or any award agreement under any such plan.

If our compensation committee determines, in its reasonable good faith and discretion, that a participant has not satisfied the conditions in the Severance Policy relating to the execution of the separation and release agreement and compliance with restrictive covenants, (i) any entitlement of the participant to receive any payments or benefits due under the Severance Policy (other than accrued payments) will be forfeited, and (ii) the participant will be obligated to promptly repay the Company all amounts of payments and benefits the participant previously received.

Clawback Policy

The Company’s Code of Business Conduct and Ethics includes clawback provisions in order to help ensure that the performance of our employees is aligned with our incentive targets and that our incentive compensation is paid or awarded based on accurate financial results. These provisions provide that if the audit committee or its designee determines, in its or their discretion, that the Company’s Code of Business Conduct and Ethics or other Company policy (including the Company’s amended and restated insider trading policy and guidelines with respect to certain transactions in securities dated December 10, 2020 (the “Insider Trading Policy”)) has been violated by an employee, then such committee or designee will review the employee’s incentive compensation in order to assess whether a penalty of disgorgement would be appropriate under the circumstances. Additionally, to the extent required or permitted by applicable law and regulations, the Company will seek the reimbursement or recoupment of any award, vesting, payment or distribution of cash, equity or other incentive compensation (“Covered Compensation”) to an executive officer of the Company (as such term is defined under Rule 3b-7 of the Exchange Act) in all instances where (i) the award (or the vesting of such award), payment or distribution of the Covered Compensation was based upon or resulted from the achievement of financial results by the Company which were the product of intentional

misconduct or fraudulent activity, violation of applicable law or regulations or violation of Company policy or were subsequently the cause or subject of a material negative restatement of any of the Company’s financial statements (collectively, “Wrongful Acts”), (ii) in the view of the board of directors such executive officer engaged in fraud or intentional misconduct known by the executive officer to be in violation of applicable laws or regulations or Company policy which caused or contributed to the Wrongful Acts, and (iii) a lower award, vesting, payment or distribution of Covered Compensation would have been provided to such executive officer in the absence of the Wrongful Acts. In each such instance, the board of directors will seek to recover such portion of such executive officer’s Covered Compensation for the relevant period as the board of directors deems appropriate after a review of the relevant facts and circumstances. Where any Covered Compensation consists of or includes an equity award, including circumstances where vesting with respect to such equity award is based on or results from the achievement of financial results, the board of directors may take such action as it deems appropriate consistent with the above principles, including, where appropriate, seeking the cancellation of stock, rights or option awards or reimbursement or recoupment of gains realized therefrom. The full text of our Code of Business Conduct and Ethics is posted on our website at https://investors.10xgenomics.com/ in the “Governance” section of our Investors webpage.

In addition, the 2019 Omnibus Incentive Plan contains clawback provisions that all awards made under the plan are subject to reduction, cancellation, forfeiture or recoupment to the extent necessary to comply with any clawback, forfeiture or other similar policy adopted by the Company or as otherwise required by law. To the extent that an award recipient receives any amount in excess of the amount that such award recipient should otherwise have received under the terms of an award for any reason (including, without limitation, by reason of a financial restatement, mistake in calculations or other administrative error), the award recipient will be required to repay any such excess amount to the Company.

Tax and Accounting Implications

We operate our compensation programs with the good faith intention of complying with Section 409A of the Code. We account for equity-based payments with respect to our long-term equity incentive award programs in accordance with the requirements of FASB ASC Topic 718, Compensation — Stock Compensation.

Summary Compensation Table

The following Summary Compensation Table summarizes the total compensation of our NEOs for all services rendered to the Company in all capacities for the fiscal years ending December 31, 2020, 2019 and 2018, except that we do not show fiscal year 2018 compensation for Dr. Hindson as he was not an NEO for the fiscal year ending December 31, 2018, fiscal year 2018 or 2019 compensation for Mr. Crutchfield as he was not an NEO for the fiscal years ending December 31, 2018 or 2019, or fiscal year 2018 or 2019 compensation for Ms. De Backer as she was not an NEO for the fiscal years ending December 31, 2018 or 2019.


Name and Principal Position	Year	Salary ($)(1)	Bonus ($)(2)	Stock Awards ($)(3)	Option Awards ($)(3)	Non-equity Incentive Plan Compensation ($)(4)	All Other Compensation ($)(5)	Total ($)
Serge Saxonov	2020	400,000	—	—	10,227,724	—	254,993	10,882,717
Chief Executive Officer	2019	393,750	—	—	1,811,712	157,500	—	2,362,962
	2018	365,833	—	—	601,010	117,432	—	1,084,275
Justin J. McAnear	2020	330,000	—	—	3,933,816	—	—	4,263,816
Chief Financial Officer	2019	325,000	18,688	—	248,561	56,062	—	648,311
	2018	71,737	—	—	1,455,118	—	—	1,526,855
Benjamin J. Hindson	2020	350,000	—	—	5,900,537	—	264,974	6,515,511
President and Chief Scientific Officer	2019	342,750	24,635	—	1,242,677	59,124	—	1,669,186
Bradford J. Crutchfield	2020	350,000	—	—	3,933,649	—	—	4,283,649
Chief Commercial Officer
Ruth De Backer(6)	2020	237,808	—	4,345,338	6,288,253	—	100,000	10,971,399
Chief Business Officer
Eric S. Whitaker	2019	334,902	24,071	—	1,056,276	57,771	—	1,473,020
General Counsel	2018	316,340	21,748	—	480,845	55,850	—	874,783

____________

(1)The amounts shown represent the base salaries earned by our NEOs in fiscal years 2018, 2019 and 2020. We did not change our named executive officers’ base salaries for 2020 except with respect to Mr. Crutchfield in connection with his transition to the Annual Incentive Plan as described below, which resulted in an increase in his annual base salary to $350,000 effective January 1, 2020.

(2)No executive bonuses were awarded for fiscal year 2020.

(3)The amounts shown represent the grant date fair value of stock options to purchase shares of our Class A common stock granted to our NEOs in fiscal year 2020, as computed in accordance with FASB ASC Topic 718. For a discussion of valuation assumptions used to determine the grant date fair value of the stock options granted to our NEOs in fiscal year 2020, see Note 9 of Notes to our Consolidated Financial Statements set forth in our Annual Report on Form 10-K for the year ended December 31, 2020. There can be no assurance that options will be exercised or that the RSUs will vest in full (in which case no value with respect to such options or RSUs will be realized by the individual) or that the value upon exercise or upon vesting, as applicable, will approximate the fair value as computed in accordance with FASB ASC Topic 718.

(4)No non-equity incentive plan compensation was awarded for the 2020 fiscal year.

(5)The amount shown for Dr. Saxonov includes (i) a $125,000 payment to cover the FTC filing fee plus an associated $126,512 tax gross up on such payment, and (ii) an accrued paid time off payout. The amount shown for Dr. Hindson includes (i) a $125,000 payment to cover the FTC filing fee plus an associated $126,512 tax gross up on such payment, and (ii) a $13,462 accrued paid time off payout. The amount shown for Ms. De Backer is for a sign-on/relocation bonus of $100,000.

(6)Ms. De Backer's employment commenced on April 27, 2020.

Grants of Plan-Based Awards

The following table summarizes the awards granted to each of the named executive officers during the fiscal year ended December 31, 2020:


Name	Grant Date(1)	Estimated Future Payouts Under Non-Equity Incentive Plan Awards - Target ($)(2)	All Other Stock Awards: Number of Shares of Stock or Units (#)	All Other Option Awards: Number of Securities Underlying Options (#)	Exercise or Base Price of Option Awards ($/share)	Grant Date Fair Value of Stock and Option Awards ($)(3)
Serge Saxonov	4/21/2020	576,000	0	235,733	74.58	10,227,724
Justin J. McAnear	4/21/2020	422,400	0	90,667	74.58	3,933,816
Benjamin J. Hindson	4/21/2020	448,000	0	136,000	74.58	5,900,537
Bradford J. Crutchfield	4/21/2020	448,000	0	90,667	74.58	3,933,649
Ruth De Backer	7/30/2020	448,000	44,563	111,407	97.51	10,633,591

____________

(1)The vesting schedule applicable to each stock option to purchase shares of our Class A common stock is set forth in the “—Outstanding Equity Awards as of December 31, 2020” table.

(2)Represents the threshold, target and maximum amount. For 2020, cash bonuses were payable at 100% if the applicable revenue target was met or exceeded and payable at 0% if the target was not met. Due to the impact of the COVID-19 pandemic, this target was not met, and therefore no bonus payouts were made to our named executive officers for 2020.

(3)The amounts shown represent the grant date fair value of stock options to purchase shares of our Class A common stock granted to our named executive officers in fiscal year 2020, as computed in accordance with FASB ASC Topic 718. For a discussion of valuation assumptions used to determine the grant date fair value of the stock options granted to our named executive officers in fiscal year 2020, see Note 9 of Notes to our Consolidated Financial Statements set forth in

our Annual Report on Form 10-K for the year ended December 31, 2020. There can be no assurance that options will be exercised (in which case no value will be realized by the individual) or that the value upon exercise will approximate the fair value as computed in accordance with FASB ASC Topic 718.

Outstanding Equity Awards as of December 31, 2020

The following table lists the outstanding equity awards held by our NEOs as of December 31, 2020:


			Stock option awards(1)
Name	Grant date		Numbers of securities underlying unexercised stock options exercisable (#)(2)	Numbers of securities underlying unexercised stock option unexercisable (#)(3)	Equity incentive plan awards: number of securities underlying unexercised unearned stock options (#)	Stock option exercise price ($)	Stock option expiration date
Serge Saxonov	10/18/2017	(4)	52,648	56,250	—	1.20	10/18/2027
	10/18/2017	(5)	62,500	50,000	—	1.20	10/18/2027
	10/18/2017	(6)	50,000	100,000	—	1.20	10/18/2027
	11/2/2018	(7)	15,140	109,375	—	5.04	11/2/2028
	5/10/2019	(8)	42,521	85,042	—	11.48	5/10/2029
	4/21/2020	(9)	39,288	196,445	—	74.58	4/21/2030
Justin J. McAnear	11/2/2018	(10)	480,159	—	—	5.04	11/2/2028
	5/10/2019	(11)	8,333	11,667	—	11.48	5/10/2029
	4/21/2020	(12)	15,111	75,556	—	74.58	4/21/2030
Benjamin J. Hindson	10/27/2015	(13)	36,364	—	—	0.88	10/27/2025
	11/18/2016	(14)	125,000	—	—	1.07	11/18/2026
	10/18/2017	(15)	134,500	37,500	—	1.20	10/18/2027
	11/2/2018	(16)	98,437	76,563	—	5.04	11/2/2028
	5/10/2019	(17)	41,666	58,334	—	11.48	5/10/2029
	4/21/2020	(18)	22,666	113,334	—	74.58	4/21/2030
Bradford J. Crutchfield	2/3/2017	(19)	630,000	—	—	1.16	2/3/2027
	10/18/2017	(20)	—	4,688	—	1.20	10/18/2017
	11/2/2018	(21)	56,979	54,688	—	5.04	11/2/2028
	5/10/2019	(22)	29,166	40,834	—	11.48	5/10/2019
	4/21/2020	(23)	15,111	75,556	—	74.58	4/21/2030
Ruth De Backer	7/30/2020	(24)	—	4,100	—	97.51	7/30/2030
	7/30/2020	(25)	—	44,563	—	—	7/30/2030
	7/30/2020	(26)	—	107,307	—	97.51	7/30/2030

______________

(1)With the exception of the stock options granted on or after April 21, 2020, all of the stock options held by each of our NEOs as of December 31, 2020 are eligible to receive accelerated vesting, such that 50% of the then-unvested portion of the stock options will vest and become exercisable immediately prior to a change of control (as defined in our Amended and Restated 2012 Stock Plan), and 100% of the then-unvested portion of the stock options will vest and become exercisable if the NEO’s employment is terminated without cause (as defined in our Amended and Restated 2012 Stock Plan) in connection with or following a change of control. The stock options granted on or after April 21, 2020 are eligible to receive accelerated vesting, such that 100% of the then-unvested portion of the stock options will vest and become exercisable immediately prior to a change in control (as defined in the 10x Genomics, Inc. Change in Control Severance Policy) if the NEO incurs a qualified termination (as defined in the 10x Genomics, Inc. Change in Control Severance Policy).

(2)The amounts shown represent stock options to purchase shares of our Class A common stock that are (i) early exercisable (meaning that the stock options may be exercised before they vest in exchange for a restricted stock award

for shares of our Class A common stock) and have vested or have not yet vested or (ii) not early exercisable and have vested.

(3)The amounts shown represent stock options to purchase shares of our Class A common stock that are not early exercisable and have not yet vested.

(4)1/48th of the stock option vested on the one month anniversary of September 1, 2017, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Saxonov’s continued service through each applicable vesting date.

(5)Because our board of directors determined that our total revenue target of $140 million was achieved for fiscal year 2018, 1/36th of the stock option vested on January 1, 2019, and 1/36th of the stock option vested, and continues to vest, on the same day of each month thereafter, subject to Dr. Saxonov’s continued service through each applicable vesting date.

(6)1/36th of the stock option was eligible to vest in equal monthly installments beginning on January 1, 2020 if our board of directors determined that that our total revenue target of $230 million is achieved for fiscal year 2019, subject to Dr. Saxonov’s continued service through each applicable vesting date. Following December 31, 2019, our board of directors determined that our total revenue target of $230 million was achieved for fiscal year 2019 and 1/36th of the stock option vested on January 1, 2020, and 1/36th of the stock option vested, and continues to vest, on the same day of each month thereafter, subject to Dr. Saxonov’s continued service through each applicable vesting date.

(7)1/48th of the stock option vested on the one month anniversary of September 1, 2018, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Saxonov’s continued service through each applicable vesting date.

(8)1/48th of the stock option vested on the one month anniversary of April 1, 2019, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Saxonov’s continued service through each applicable vesting date.

(9)1/48th of the stock option vested on the one month anniversary of April 1, 2020, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Saxonov’s continued service through each applicable vesting date.

(10)12/48th of the early exercisable stock option vested on the 12 month anniversary of October 8, 2018, and 1/48th of the early exercisable stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter over the following three years, subject to Mr. McAnear’s continued service through each applicable vesting date.

(11)1/48th of the stock option vested on the one month anniversary of April 1, 2019, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Mr. McAnear’s continued service through each applicable vesting date.

(12)1/48th of the stock option vested on the one month anniversary of April 1, 2020, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Mr. McAnear’s continued service through each applicable vesting date.

(13)All shares subject to the stock option grant were vested and exercisable as of December 31, 2020.

(14)All shares subject to the stock option grant were vested and exercisable as of December 31, 2020.

(15)1/48th of the stock option vested on the one month anniversary of September 1, 2017, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Hindson’s continued service through each applicable vesting date.

(16)1/48th of the stock option vested on the one month anniversary of September 1, 2018, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Hindson’s continued service through each applicable vesting date.

(17)1/48th of the stock option vested on the one month anniversary of April 1, 2019, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Hindson’s continued service through each applicable vesting date.

(18)1/48th of the stock option vested on the one month anniversary of April 1, 2020, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Dr. Hindson’s continued service through each applicable vesting date.

(19)12/48th of the early exercisable stock option vested on the 12 month anniversary of February 2, 2017, and 1/48th of the early exercisable stock option vested, and continued to vest, in equal monthly installments on the same day of each month thereafter over the following three years, subject to Mr. Crutchfield’s continued service through each applicable vesting date.

(20)1/48th of the stock option vested on the one month anniversary of September 1, 2017, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Mr. Crutchfield’s continued service through each applicable vesting date.

(21)1/48th of the stock option vested on the one month anniversary of September 1, 2018, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Mr. Crutchfield’s continued service through each applicable vesting date.

(22)1/48th of the stock option vested on the one month anniversary of April 1, 2019, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Mr. Crutchfield’s continued service through each applicable vesting date.

(23)1/48th of the stock option vested on the one month anniversary of April 1, 2020, and 1/48th of the stock option vested, and continues to vest, in equal monthly installments on the same day of each month thereafter, subject to Mr. Crutchfield’s continued service through each applicable vesting date.

(24)1/4th of the stock option will vest on the twelve month anniversary of April 27, 2020, and 1/48th of the stock option will vest, and continue to vest, in equal monthly installments on the same day of each month thereafter, subject to Ms. De Backer’s continued service through each applicable vesting date.

(25)1/4th of the RSUs will vest on May 21, 2021, and 1/16th of the RSUs will vest, and continue to vest, in equal quarterly installments on the same day of each quarter thereafter, subject to Ms. De Backer’s continued service through each applicable vesting date.

(26)1/4th of the stock option will vest on the twelve month anniversary of April 27, 2020, and 1/48th of the stock option will vest, and continue to vest, in equal monthly installments on the same day of each month thereafter, subject to Ms. De Backer’s continued service through each applicable vesting date.

Options Exercises

The following table provides information concerning the exercise of stock options held by our NEOs in 2020:


	Option Awards
Name	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise ($)(1)
Serge Saxonov	134,296	12,675,446
Justin J. McAnear	119,841	12,299,652
Benjamin J. Hindson	441,636	43,830,470
Bradford J. Crutchfield	203,645	21,575,834
Ruth De Backer	—	—

______________

(1)Value realized on exercise is equal to the difference between the market price of the underlying shares at exercise and the exercise price of the options and does not necessarily reflect actual proceeds received.

Pension Benefits and Nonqualified Deferred Compensation

Our named executive officers do not participate in any pension or nonqualified deferred compensation plans and received no pension benefits or nonqualified deferred compensation during the fiscal year 2020.

Employment Arrangements with Named Executive Officers

This section contains a description of the material terms of the employment arrangements with our NEOs. Our executive officers, other than Drs. Saxonov and Hindson, signed offer letters with us, which provides for at-will employment and sets forth other terms of employment, including the initial base salary, target incentive opportunity and the terms of the initial equity grant and in the case of Mr. McAnear, severance protections upon a qualifying termination prior to October 8, 2019. In addition, each of our executive officers executed a form of our standard at-will employment, confidential information, invention assignment and arbitration agreement, which includes a non-solicit of employees covenant during employment and for one year following termination.

Dr. Saxonov

Dr. Saxonov co-founded our company in 2012 and has not been party to an offer letter with us since our inception. In fiscal year 2020, Dr. Saxonov was entitled to an annual base salary of $400,000, and was eligible to earn an annual target bonus equal to 44% of his eligible base salary.

Mr. McAnear

Mr. McAnear signed an offer letter with us on August 17, 2018, under which he is entitled to an annual base salary of $310,000, which was increased to $330,000 annualized effective April 1, 2019 and is eligible to earn an annual target bonus equal to 23% of his eligible base salary (increased to 28% effective January 1, 2020). Mr. McAnear’s offer letter provides that he is eligible to participate in employee benefit plans that are generally available to other senior executives of our company located in the United States.

Dr. Hindson

Dr. Hindson co-founded our company in 2012 and has not been party to an offer letter with us since our inception. In fiscal year 2020, Dr. Hindson was entitled to an annual base salary of $350,000 and was eligible to earn an annual target bonus equal to 28% of his eligible base salary.

Mr. Crutchfield

Mr. Crutchfield signed an offer letter with us on November 29, 2016, under which he is entitled to an annual base salary of $295,000, which was increased to $311,148 annualized effective March 1, 2018 and to $330,000 annualized effective April 1, 2019. As described above, in 2020 Mr. Crutchfield no longer participated in a sales incentive plan and instead participated in our Annual Incentive Plan which resulted in a decrease in his discretionary annual target bonus to an amount equal to 28% of his eligible base salary. In order to partially offset this reduction in annual target bonus opportunity, Mr. Crutchfield’s base salary was increased to $350,000 effective January 1, 2020. In addition, Mr. Crutchfield is eligible to participate in employee benefit plans that are generally available to other senior executives of our company located in the United States.

Ms. De Backer

Ms. De Backer signed an offer letter with us on April 2, 2020, under which she is entitled to a $100,000 sign-on/ relocation bonus and annual base salary of $350,000 and is eligible to earn a discretionary annual target bonus equal to 28% of her eligible base salary. In addition, Ms. De Backer is eligible to participate in employee benefit plans that are generally available to other senior executives of our company located in the United States.

Potential Payments Upon a Change of Control or Termination of Employment

Effective July 30, 2020, our compensation committee adopted the 10x Genomics, Inc. Change in Control Severance Policy (the “Severance Policy”), which covers our NEOs with double trigger change of control severance benefits. As described in “Severance Arrangements—Change in Control Severance Policy,” our NEOs are eligible to receive certain severance payments and benefits under the Severance Policy upon a termination of employment by the Company without cause or by the NEO for good reason within 24 months following a change in control. In the event of such a termination, each NEO is entitled to severance equal to 6 months of base salary, reimbursement for a portion of COBRA premiums for 6 months, and accelerated vesting of any outstanding stock option or restricted stock unit awards.

Additionally, with the exception of the stock options and RSUs granted on or after April 21, 2020 (which options and RSUs are entitled to accelerated vesting under the terms of the Severance Policy), all of the stock options held by each of our NEOs as of December 31, 2020 are eligible to receive accelerated vesting, such that 50% of the then-unvested portion of the stock options will vest and become exercisable immediately prior to a change of control (as defined in our Amended and Restated 2012 Stock Plan), and 100% of the then-unvested portion of the stock options will vest and become exercisable if the NEO’s employment is terminated without cause (as defined in our Amended and Restated 2012 Stock Plan) in connection with or following a change of control.

We have no provisions for severance in place in the event of a termination of employment outside of a change of control for Drs. Saxonov and Hindson, and Messrs. McAnear and Crutchfield. As part of the offer to join 10x Genomics, it was agreed that Ms. De Backer would be provided a lump sum payment of $500,000 in the event she is terminated by us prior to May 21, 2021 involuntarily without Cause (as defined in the offer letter).


Name	Payment Type	Termination Without Cause Or For Good Reason (Including Non-Extension of Term) ($)	Termination Without Cause Or For Good Reason Upon a Change in Control ($)
Dr. Saxonov	Cash Severance(1)	—	200,000
	Benefit Continuation(2)	—	10,574
	Equity Awards(3)	—	68,125,163
	Total	—	68,335,737
Mr. McAnear	Cash Severance(1)	—	165,000
	Benefit Continuation(2)	—	18,727
	Equity Awards(3)	—	44,135,875
	Total	—	44,319,602
Mr. Crutchfield	Cash Severance(1)	—	175,000
	Benefit Continuation(2)	—	6,039
	Equity Awards(3)	—	23,184,900
	Total	—	23,365,939
Dr. Hindson	Cash Severance(1)	—	175,000
	Benefit Continuation(2)	—	18,727
	Equity Awards(3)	—	30,906,510
	Total	—	31,100,237
Ms. De Backer	Cash Severance(1)	500,000	175,000
	Benefit Continuation(2)	—	10,904
	Equity Awards(3)	—	11,222,056
	Total	500,000	11,407,960

(1) For termination without cause or for good reason upon a change of control, amount represents 6 months of salary based on each NEO's respective salary in effect December 31, 2020.

(2) For termination without cause or for good reason upon a change of control, amount represents monthly payments equal to the COBRA premiums in effect for 2020 required for 6 months.

(3) Amounts in this line represent a cash payout of all stock options and RSUs that were not vested at December 31, 2020 and would vest pursuant to their terms or the terms of the Severance Policy.

Compensation Risk Assessment

The compensation committee annually reviews the risks that may arise from our compensation programs. In 2020, our compensation committee reviewed the design of each of our compensation programs in order to determine whether any of our programs create or encourage excessive or inappropriate risk-taking. Based on their review, the compensation committee concluded that our compensation programs do not present any risk that is reasonably likely to have a material adverse effect on us.

Prohibition on Hedging, Pledging, and Short Sales

Pursuant to our Insider Trading Policy, all Company personnel, including our directors, officers, employees, and agents (such as independent contractors, and consultants) are prohibited from engaging in hedging, and transactions in derivatives of our securities, except for a few limited exceptions. These limited exceptions include the entry into a transaction involving an exchange fund if such transaction is pre-cleared in accordance with our Insider Trading Policy or the exercise of stock options issued under our benefit plans or other compensatory arrangements in accordance with such plans or arrangements. Furthermore, our Insider Trading Policy prohibits (a) pledging of Company securities as collateral by Company personnel without first obtaining pre-clearance from one of our compliance officers and (b) holding Company securities in margin accounts and short sales of Company securities, without exception. The foregoing restrictions are designed, among other things, to prohibit our directors, executive officers and other insiders from insulating themselves from the effects of poor stock price performance.

As part of the administration of our Insider Trading Policy, we have procedures in place that are reasonably designed to prevent prohibited transactions from being initiated by our directors, officers and employees.

Chief Executive Officer Pay Ratio

The 2020 annual total compensation of our Chief Executive Officer was $10,882,717, while the 2020 annual total compensation of our median compensated employee was $203,195. Based on the foregoing, the ratio of the annual total compensation of our Chief Executive Officer to the median of the annual total compensation of our employees was 54 to 1.

We determined our median compensated employee in 2020 by using base salaries, bonuses, commissions and the grant date fair value of equity awards granted to employees in 2020 as our consistently applied compensation measure. Compensation paid in foreign currencies was converted to U.S. dollars using the average exchange rate on December 31, 2020. In addition, we annualized base salaries for permanent full-time and part-time employees that did not work the full year. We made no other assumptions, cost-of-living adjustments or other estimates.

We applied this measure to our global employee population, exclusive of our Chief Executive Officer and the employees excluded under the de minimis exemption described below, as of December 31, 2020, the last day of our 2020 fiscal year. As of December 31, 2020, we had 852 employees, with 681 of those employees based in the United States and 171 of those employees located outside of the United States. We applied the “de minimis” exemption to our pay ratio calculation to exclude 35 of our non-U.S. employees accounting for 4.1% of our total workforce in the following countries: Australia (2); Austria (1); Canada (8); China (9); Denmark (2); Hong Kong (1); India (2); Japan (7); Korea (1); Switzerland (1) and Taiwan (1). After taking into account the de minimis exemption, 681 employees in the United States and 136 employees located outside of the United States were considered in identifying our median compensated employee.

After identifying the median compensated employee, we calculated the employee’s 2020 annual total compensation in accordance with Item 402(c)(2)(x) of Regulation S-K, which is the same methodology we used to calculate our Chief Executive Officer’s annual total compensation in the table above entitled “Summary Compensation Table.”

Because the SEC rules for identifying the median compensated employee and calculating the pay ratio allow companies to use different methodologies, exemptions, estimates and assumptions, the pay ratio reported above may not be comparable to the pay ratio reported by other companies as other companies may have different employment and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.

Limitation of Liability and Indemnification

Our amended and restated certificate of incorporation provides that no director would be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except as required by applicable law. Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for the following:

•any breach of the director’s duty of loyalty to our company or our stockholders;

•any act or omission not in good faith or which involved intentional misconduct or a knowing violation of law;

•unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; and

•any transaction from which the director derived an improper personal benefit.

As a result, neither we nor our stockholders has the right, through stockholders’ derivative suits on our behalf, to recover monetary damages against a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations described above.

Our amended and restated bylaws also provide that, to the fullest extent permitted by law, we will indemnify any officer or director of our company against all damages, claims and liabilities arising out of the fact that the person is or was our director or officer, or served any other enterprise at our request as a director or officer. Amending this provision would not reduce our indemnification obligations relating to actions taken before an amendment.

Equity Compensation Plan Information

The following table provides information as of December 31, 2020 with respect to shares of our common stock that may be issued under our existing equity compensation plans.


Plan Category	Number of Securities to be Issued upon Exercise of Outstanding Options, Restricted Stock Units and Rights	Weighted Average Exercise Price of Outstanding Options and Rights		Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in the first Column)
Equity compensation plans approved by security holders
Amended and Restated 2012 Stock Plan(1)	9,601,093	$	6.35	—
2019 Omnibus Incentive Plan(2)	2,259,751	$	72.04	8,267,389
2019 Employee Stock Purchase Plan(3)	—	—		1,836,273
Equity compensation plans not approved by security holders	—	—		—
TOTAL	11,860,844	$	18.86	10,103,662

____________

(1)Our board of directors adopted, and our stockholders approved, the Amended and Restated 2012 Stock Plan (the “2012 Plan”). As a result of our initial public offering and the adoption of the 2019 Omnibus Incentive Plan (the “2019 Plan”), we no longer grant awards under the 2012 Plan; however, all outstanding options issued pursuant to the 2012 Plan continue to be governed by their existing terms. To the extent that any such awards are forfeited or lapse unexercised or are repurchased, the shares of common stock subject to such awards will become available for issuance under the 2019 Plan.

(2)Our 2019 Plan provides that the number of shares available for issuance under the 2019 Plan will be increased on the first day of each fiscal year beginning with the 2021 fiscal year, in an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of our Class A common stock as determined by our board of directors. However, if on January 1 of a calendar year, our board of directors has not either confirmed the 5% increase described in clause (i) or approved a lesser number of shares of our Class A common stock for such calendar year, then our board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year.

(3)Our 2019 Employee Stock Purchase Plan (the “ESPP”) provides that the number of shares available for issuance under the ESPP will be increased on the first day of each fiscal year beginning with the 2021 fiscal year, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of our Class A common stock as determined by our board of directors. However, if on January 1 of a calendar year our board of directors has not either confirmed the 1% increase described in clause (i) or approved a lesser number of shares of our Class A common stock for such calendar year, then our board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year.

STOCK OWNERSHIP

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 31, 2021 for:

•each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;

•each of our named executive officers;

•each of our directors and nominees for director; and

•all of our current executive officers and directors as a group.

We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.

We have based our calculation of the percentage of beneficial ownership on 87,080,908 shares of our Class A common stock and 22,531,465 shares of our Class B common stock outstanding as of March 31, 2021. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60 days of March 31, 2021, to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

Each share of our Class B common stock is convertible at any time at the option of the holder into one share of our Class A common stock. Holders of our Class A common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and holders of our Class B common stock are entitled to ten votes for each share held.

Unless otherwise indicated, the address for each listed stockholder is: c/o 10x Genomics, Inc., 6230 Stoneridge Mall Road, Pleasanton, California 94588. To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock.


	Shares Beneficially Owned
	Class A common stock			Class B common stock
Name and address of beneficial owner	Number	Percent		Number	Percent
Named Executive Officers and Directors:
Serge Saxonov(1)	1,324,038	1.5	%	3,031,865	13.5	%
Benjamin J. Hindson(2)	476,862	*		3,000,000	13.3	%
Justin J. McAnear(3)	496,927	*		—	—
Brad Crutchfield(4)	748,248	*		—	—
Ruth De Backer(5)	42,164	*		—	—
John R. Stuelpnagel(6)	447,553	*		2,105,736	9.3	%
Sri Kosaraju(7)	132,562	*		—	—
Mathai Mammen(8)	204,062	*		—	—
Kimberly J. Popovits(9)	8,079	*		—	—
Bryan E. Roberts(10)	241,575	*		—	—
Shehnaaz Suliman(11)	104,062	*		—	—
All executive officers and directors as a group (13 persons)(12)	4,542,018	5.1	%	8,137,601	36.1	%


	Shares Beneficially Owned
	Class A common stock			Class B common stock
Name and address of beneficial owner	Number	Percent		Number	Percent
5% Stockholders:
Foresite Capital Management and affiliated entities(13)	7,507,056	8.6	%	—	—
Venrock and affiliated entities(14)	2,037,825	2.3	%	5,790,422	25.7	%
Fidelity and affiliated entities(15)	10,071,083	11.8	%	6,570,733	29.2	%
Morgan Stanley and affiliated entities(16)	5,915,534	6.8	%	—	—
Meritech Capital Partners and affiliated entities(17)	5,161,950	5.9	%	—	—
BlackRock, Inc.(18)	5,163,020	5.9	%	—	—
Paladin Capital Management, LLC and affiliates entities(19)	8,249,355	9.5	%	—	—
The Vanguard Group and affiliated entities(20)	6,187,705	7.1	%	—	—

_______________

* Less than 1%.

(1)Consists of (a) 880,468 shares of Class A common stock, (b) 89,960 shares of Class A common stock held by Y/S Descendants Trust, (c) 353,610 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2021, (d) 1,281,865 shares of Class B common stock and (e) 1,750,000 shares of Class B common stock held by Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust of which Dr. Saxonov is the sole trustee.

(2)Consists of (a) 3,000,000 shares of Class B common stock held by the Hindson Family Revocable Trust, (b) 36,636 shares of Class A common stock and (c) 440,226 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2021.

(3)Consists of (a) 30,357 shares of Class A common stock, (b) 440,159 shares of Class A common stock issuable pursuant to stock options that may be early exercised at any time (227,659 shares of which vest within 60 days of March 31, 2021) and (b) 26,411 shares of Class A common stock issuable pursuant to additional stock options exercisable within 60 days of March 31, 2021.

(4)Consists of (a) 34,608 shares of Class A common stock and (b) 713,640 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2020.

(5)Consists of (a) 30,171 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2021 and (b) 11,140 shares of Class A common stock underlying RSUs that vest within 60 days of March 31, 2021.

(6)Consists of (a) 2,105,736 shares of Class B common stock held by the John R. Stuelpnagel Trust of which Dr. Stuelpnagel is the sole trustee, (b) 443,491 shares of Class A common stock (53,125 shares of which were subject to our right of repurchase as of March 31, 2021) and (c) 4,062 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2020.

(7)Consists of (a) 19,333 shares of Class A common stock held by the Kosaraju Family Trust dated June 21, 2014 of which Mr. Kosaraju is trustee, (b) 109,167 shares of Class A common stock issuable pursuant to stock options that may be early exercised at any time (49,583 shares of which vest within 60 days of March 31, 2021) and (c) 4,062 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2020.

(8)Consists of (a) 200,000 shares of Class A common stock issuable pursuant to stock options that may be early exercised at any time (195,833 shares of which vest within 60 days of March 31, 2021) and (b) 4,062 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2020.

(9)Consists of 8,079 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2020.

(10)Consists of (a) 215,291 shares of Class A common stock, (b) 26,284 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2021. Dr. Roberts does not have voting and dispositive power over the shares held by Venrock and Venrock’s affiliated entities.

(11)Consists of (a) 100,000 shares of Class A common stock issuable pursuant to stock options that may be early exercised at any time (43,750 shares of which vest within 60 days of March 31, 2021) and (b) 4,062 shares of Class A common stock issuable pursuant to stock options exercisable within 60 days of March 31, 2021.

(12)Consists of (a) 1,803,699 shares of Class A common stock beneficially owned by our named executive officers, current directors and other executive officers (53,125 shares of which were subject to our right of repurchase as of March 31, 2021), (b) 2,738,319 shares of Class A common stock subject to outstanding stock options that are exercisable within 60 days of March 31, 2021 by our named executive officers, current directors and other executive officers and (c) 8,137,601

shares of Class B common stock beneficially owned by our named executive officers, current directors and other executive officers.

(13)Consists of: (a) 1,250,000 shares of Class A common stock owned directly by Foresite Capital Fund I, L.P. (“FCF I”), (b) 2,503,528 shares of Class A common stock owned directly by Foresite Capital Fund II, L.P. (“FCF II”), (c) 1,250,000 shares of Class A common stock owned directly by Foresite Capital Management I, LLC (“FCM I”), (d) 2,503,528 shares of Class A common stock owned directly by Foresite Capital Management II, LLC (“FCM II”). Based solely upon a Schedule 13G/A filed by FCF I, FCF II, FCM I, FCM II and James Tananbaum with the SEC on February 16, 2021 (the “Foresite 13G”): FCM I, is the general partner of FCF I and may be deemed to have sole voting and dispositive power over shares held by FCF I; FCM II is the general partner of FCF II and may be deemed to have sole voting and dispositive power over shares held by FCF II; James B. Tananbaum (“Mr. Tananbaum”), in his capacity as managing member of FCM I and FCM II, may be deemed to have sole voting and dispositive power over such shares; and each of the entities identified in this footnote is c/o Foresite Capital Management, 600 Montgomery Street, Suite 4500, San Francisco CA, 94111.

(14)Based upon a Schedule 13G/A filed by Venrock Associates VI, L.P. (“VA VI”), Venrock Partners VI, L.P. (“VP VI”), Venrock Management VI, LLC and Venrock Partners Management VI, LLC with the SEC on February 16, 2021 (the “Venrock 13G”), as of December 31, 2020, Venrock’s ownership consisted of: (a) 1,889,497 shares of Class A common stock and 5,368,880 shares of Class B common stock held by VA VI and (b) 148,328 shares of Class A common stock and 421,542 shares of Class B common stock held by VP VI. Pursuant to the Venrock 13G: Venrock Management VI, LLC is the general partner of VA VI and Venrock Partners Management VI, LLC is the general partner of VP VI, and the address of each of the entities and individuals identified in this footnote is c/o Venrock, 3340 Hillview Avenue, Palo Alto, CA 94304 for its Palo Alto office and 7 Bryant Park, 23rd Floor, New York, NY 10018 for its New York Office.

(15)Consists of 6,570,733 shares of Class B Common Stock directly owned by investment companies advised by Fidelity Management & Research Company LLC (“FMR Co.”) an indirect wholly-owned subsidiary of FMR LLC. Based upon a Schedule 13G/A filed by FMR LLC with the SEC on February 8, 2020 (the “Fidelity 13G/A”) on behalf of itself and Abigail P. Johnson (the “Fidelity Entities”), as of December 30, 2020, the Fidelity Entities beneficially owned 10,071,083 shares of Class A common stock. Pursuant to the Fidelity 13G/A: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC; Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC; the Johnson family group and all other Series B shareholders have entered into a shareholders’ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares and, accordingly, through their ownership of voting common shares and the execution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC; neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (“Fidelity Funds”) advised by FMR Co., which power resides with the Fidelity Funds’ Boards of Trustees; FMR Co carries out the voting of the shares under written guidelines established by the Fidelity Funds’ Boards of Trustees; and the address for FMR LLC is 245 Summer Street, Boston, MA 02210.

(16)Based upon the Schedule 13G/A filed by Morgan Stanley and Morgan Stanley Investment Management Inc. (together, “MS”) with the SEC on February 10, 2021 (the “Morgan Stanley 13G”), as of December 31, 2020, MS’s ownership consisted of 5,915,534 shares of Class A common stock. The address for each of the entities identified in this footnote is 1585 Broadway, New York, NY 10036.

(17)Based upon the Schedule 13G/A filed by Meritech Capital Partners V L.P. (“MCP V”) with the SEC on February 16, 2021 (the “Meritech 13G”), as of December 31, 2020, Meritech Capital Partners’ ownership consisted of: (a) 2,104,329 shares of Class A common stock held by MCP V, (b) 73,042 shares of Class A common stock held by Meritech Capital Affiliates V L.P. (“MC AFF V”), (c) 403,604 shares of Class A common stock held by Meritech Capital Partners V Sidecar L.P. (“MC Sidecar V”) and 2,580,975 shares of Class A common stock held by Meritech Capital Associates V L.L.C. (“MCA V”). Pursuant to the Meritech 13G, MCA V is the general partner of each of MCP V, MC AFF V and MCV Sidecar V, and may be deemed to have indirect beneficial ownership of such shares. The address of each of the entities is Meritech Capital Partners, 245 Lytton Ave, Suite 125, Palo Alto, CA 94301.

(18)Based upon the Schedule 13G filed by BlackRock, Inc. with the SEC on February 2, 2021, as of December 31, 2020, BlackRock, Inc.’s ownership consisted of 5,163,020 shares of Class A common stock owned. The address for the entity identified in this footnote is 55 East 52nd Street New York NY 10055.

(19)Based on the Schedule 13G/A filed by Paladin Capital Management, LLC and its affiliated entities and Michael Robert Steed with the SEC on February 12, 2021 (the “Paladin 13G”), as of December 31, 2020, consists of: (1) 2,028,052 shares of Class A common stock held by Paladin Capital Management, LLC (“Paladin”), (b) 1,636,125 shares of Class A common stock held by Paladin Holdings III, L.P. (“Paladin III”), (c) 391,927 shares of Class A common stock held by Paladin Holdings III (Cayman Islands), L.P. (“Paladin III Cayman”), (d) 1,636,125 shares of Class A common stock held by Paladin Capital Group III, LLC (“Paladin Group”), (e) 391,927 shares of Class A common stock held by Paladin

Homeland Security Corporation III, Ltd. (“Paladin Homeland”), (f) 676,140 shares of Class A common stock held by Paladin III, LP (“Paladin LP”), (g) 570,657 shares of Class A common stock held by Paladin III (NY City), LP (“Paladin NY LP”), (h) 391,927 shares of Class A common stock held by Paladin III (Cayman Islands), LP (“Paladin Cayman LP”), (i) 194,664 shares of Class A common stock held by Paladin III (HR), LP (“Paladin HR LP”), (j) 194,664 shares of Class A common stock held by Paladin III (CA), LP (“Paladin CA LP”), and (k) 137,147 shares of Class A common stock held by Michael Robert Steed (“Steed”). Pursuant to the Paladin 13G: Paladin Group is the general partner of Paladin III, which is the general partner of the US Funds; Paladin Homeland is the general partner of Paladin III Cayman, which is the general partner of the Cayman Fund; Steed is the managing partner of Paladin, and ultimately controls Paladin Group and Paladin Homeland, which control the general partners of the US Funds and the Cayman Fund; and the address of each entity of each of the entities is Paladin Capital Management Group, LLC, 2020 K Street, NW, Suite 620, Washington DC 20006.

(20)Based upon the Schedule 13G filed by The Vanguard Group with the SEC on February 10, 2021, as of December 31, 2020, The Vanguard Group’s ownership consisted of 6,187,705 shares of Class A common stock held by Vanguard Asset Management, Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisors, LLC, Vanguard Group (Ireland) Limited, Vanguard Investments Australia Ltd., Vanguard Investments Canada Inc., Vanguard Investment Hong Kong Limited and Vanguard Investments UK, limited, collectively. The address of the reporting entity identified in this footnote is 100 Vanguard Blvd. Malvern, PA 19355.

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following is a description of transactions since January 1, 2020 to which we have been a party, in which the amount involved exceeds $120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest.

Other than as described below, there have not been, nor are there any currently proposed, transactions meeting this criteria to which we have been or will be a party other than our compensation arrangements, including employment, termination of employment and change in control arrangements, which are described where required under the sections titled “Executive Compensation” and “Director Compensation.”

Amended and Restated Investors’ Rights Agreement

We are party to our Amended and Restated Investors’ Rights Agreement (the “IRA”), dated as of October 18, 2018, which provides, among other things, that certain holders of our capital stock, including Dr. Saxonov, our Chief Executive Officer, Dr. Hindson, our Chief Scientific Officer, the John R. Stuelpnagel Trust and entities affiliated with each of Fidelity, Foresite Capital Management, Meritech Capital Partners, Softbank and Venrock and certain of their transferees, have the right to demand that we file a registration statement or request that their shares of our capital stock be covered by a registration statement that we are otherwise filing. Dr. Roberts, a member of our board of directors, is affiliated with Venrock. Dr. Stuelpnagel, the chairman of our board of directors, is trustee of the John R. Stuelpnagel Trust. The registration and associated rights set forth in the IRA will expire no later than September 11, 2021, which is two years following the completion of our initial public offering.

Stock Option Grants to Directors and Executive Officers

We have granted stock options to our directors and executive officers. For more information regarding the stock options and stock awards granted to our directors and named executive officers in 2020 see the sections titled “Executive Compensation” and “Director Compensation.”

Limitation of Liability and Indemnification of Directors and Officers

Our amended and restated certificate of incorporation provides that no director would be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except as required by applicable law. For more information regarding the limitations of liability and indemnification see the section titled “Limitation of Liability and Indemnification.”

Related Party Transaction Policy

We have adopted a formal written policy that applies to our executive officers, directors, holders of more than five percent of any class of our voting securities and any member of the immediate family of, and any entity affiliated with, any of the foregoing persons. Such persons are not permitted to enter into a related-party transaction with us without the prior consent of our audit committee, or other independent members of our board of directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an executive officer, director, principal stockholder or any of their immediate family members or affiliates in which the amount involved exceeds $120,000 must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available and deemed relevant to our audit committee, including, but not limited to, whether the transaction will be on terms no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances and the extent of the related-party’s interest in the transaction.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Proxy Statement contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are subject to the “safe harbor” created by those sections and that represent the Company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the Company’s future compensation decisions, organization and performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. The Company’s performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the Company with the Securities and Exchange Commission. The forward-looking statements set forth the Company’s beliefs as of the date that such information was first provided, and the Company assumes no duty to update the forward-looking statements contained in this Proxy Statement to reflect any change except as required by law.

OTHER MATTERS

Delinquent Section 16(A) Reports

Section 16(a) of the Exchange Act requires our directors and officers and holders of more than 10% of our common stock to file with the SEC initial reports of ownership of our common stock and other equity securities on a Form 3 and reports of changes in such ownership on a Form 4 or Form 5. Directors and officers and holders of 10% of our common stock are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. To our knowledge, based solely on a review of our records and representations made by our directors and officers regarding their filing obligations, all Section 16(a) filing requirements were satisfied with respect to the fiscal year ended December 31, 2020.

Fiscal Year 2020 Annual Report and SEC Filings

Our financial statements for our fiscal year ended December 31, 2020 are included in our Annual Report on Form 10-K filed with the SEC on February 26, 2021 (File No. 001-39035). This Proxy Statement and our Annual Report are posted on the Company’s website at https://investors.10xgenomics.com/ in the “Filings and Financials” section of the Investors webpage and are available from the SEC at its website at www.sec.gov. You may also obtain a copy of our Annual Report without charge by sending a written request to 10x Genomics, Inc., Attn: Secretary, 6230 Stoneridge Mall Road, Pleasanton, California 94588.

Company Website

We maintain a website at www.10xgenomics.com. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this Proxy Statement, and references to our website address in this Proxy Statement are inactive textual references only.

PROPOSALS OF STOCKHOLDERS FOR OUR 2022 ANNUAL MEETING

Stockholders may present proper proposals for inclusion in our proxy statement and for consideration at the next annual meeting of stockholders by submitting their proposals in writing to our Secretary in a timely manner. For a stockholder proposal to be considered for inclusion in our proxy statement for our 2022 annual meeting of stockholders, our Secretary must receive the written proposal at our principal executive offices not later than December 24, 2021. In addition, stockholder proposals must comply with the requirements of Rule 14a-8 under the Exchange Act regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Stockholder proposals should be addressed to:

10x Genomics, Inc.

Attn: Secretary

6230 Stoneridge Mall Road

Pleasanton, CA 94588

Our amended and restated bylaws establish an advance notice procedure for stockholders who wish to present a proposal before an annual meeting of stockholders (including a proposal to be included in our proxy statement). Our amended and restated bylaws provide that the only business that may be conducted at an annual meeting is business that is (a) pursuant to a notice of meeting (or any supplement thereto) delivered pursuant to Section 2.04 of our amended and restated bylaws, (b) by or at the direction of our board of directors or any authorized committee thereof or (c) by any stockholder of 10x Genomics, Inc. who is entitled to vote at the meeting and who complied with the notice procedures set forth in paragraphs (A)(2) and (A)(3) of Section 2.03 of our amended and restated bylaws and who was a stockholder of record at the time such notice is delivered to our Secretary. To be timely for our 2022 annual meeting of stockholders, our Secretary must receive the written notice at our principal executive offices:

•not earlier than February 11, 2022; and

•not later than March 13, 2022.

In the event that we hold our 2022 annual meeting of stockholders more than 30 days before or more than 70 days after June 11, 2022, then notice of a stockholder proposal that is not intended to be included in our proxy statement must be received no earlier than the close of business on the 120th day before such annual meeting and no later than the close of business on the later of the following two dates:

•the 90th day prior to such annual meeting; or

•the 10th day following the day on which public announcement of the date of such annual meeting is first made.

If a stockholder who has notified us of his, her or its intention to present a proposal at an annual meeting does not appear to present his, her or its proposal at such annual meeting, we are not required to present the proposal for a vote at such annual meeting. We reserve the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with the requirements of our amended and restated bylaws or other applicable requirements.

Nomination of Director Candidates

You may propose director candidates for consideration by our nominating and corporate governance committee by providing the information required by our amended and restated bylaws. Any such recommendations should include, among other things outlined in our amended and restated bylaws, the nominee’s name and qualifications for membership on our board of directors and should be directed to our Secretary at the address set forth above.

In addition, our amended and restated bylaws permit stockholders to nominate directors for election at an annual meeting of stockholders. To nominate a director, the stockholder must provide the information required by our amended and restated bylaws. In addition, the stockholder must give timely notice to our Secretary in accordance with our amended and restated bylaws, which, in general, require that the notice be received by our Secretary within the time period described above.

Availability of Bylaws

A copy of our amended and restated bylaws may be obtained by accessing our public filings on the SEC’s website at www.sec.gov. You may also contact our Secretary at our principal executive office for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.

Our board of directors does not know of any matter to be brought before the 2021 Annual Meeting other than the matters set forth in the Notice of 2021 Annual Meeting of Stockholders and matters incident to the conduct of the 2021 Annual Meeting. If any other matter should properly come before the 2021 Annual Meeting, the persons named in the enclosed proxy card will have discretionary authority to vote all proxies with respect thereto in accordance with their best judgment. It is important that your shares of common stock be represented at the 2021 Annual Meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote by telephone, by using the Internet or by mail at your earliest convenience, as instructed on the Notice of Internet Availability of Proxy Materials.


			By order of the Board of Directors,

			Serge Saxonov
			Chief Executive Officer and Director
April 23, 2021

SEC Form DEF 14A filed by 10x Genomics, Inc.